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 There is an urgent need for predictive drug screening and biological discovery 
tools, as the current standard systems either lack physiological relevance or are 
logistically incompatible with large-scale screens.  Here, we present a solution to this 
problem – a novel droplet-based workflow to fabricate, culture, and assess cell-matrix 
interactions on short (<7days) and long (>28 days) timescales.  With this technology, we 
can assess 3D cell-ECM interactions in a high-throughput and high-content manner, 
opening new avenues for assessing cell performance in response to therapies in a 3D 
microenvironment.  The specific applications of this platform are broad, and we 
demonstrated the applicability for this technology to improve collagen contraction assays, 
endothelial barrier function measurements, and human liver model systems for toxicity 
studies. We also show that microtissue constructs can be cryopreserved, which allows 
this technology to be disseminated more broadly, as only standard cell culture equipment 
is needed to culture microtissues after fabrication. Because of the low reagent volumes 
and small cell numbers required for our system, this platform could become a logistically 
feasible answer to 3D functional screening of samples (e.g. tumor biopsies) on a patient-
by-patient basis.  We are eager to continue to refine and expand the capabilities of our 
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Chapter 1:  Design considerations for in vitro model systems 
Introduction 
Drug discovery relies heavily on model systems to identify, develop, and test 
drugs before beginning clinical trials in humans.  This workflow is predicated on the idea 
that the behaviors seen in model systems will be good predictors of performance in 
clinical trials, but this is often not the case. Poor representation of human organs and 
disease states often leads to failure of drugs during late-stage clinical trials, significantly 
increasing the time and cost required to bring new therapies to market1. 
 
Model systems for drug discovery – animal models 
The use of animal models in medical research has resulted in improved 
understanding of disease progression, treatments, and outcomes in humans.  There are 
many in vivo platforms used for drug discovery including, but not limited to, Drosophila, 
C. elegans, mice, rats, rabbits, dogs, cats and non-human primates1–3. Each animal model 
offers advantages and disadvantages in studying human pathologies, making them useful 
in certain types of studies or phases of drug discovery.  
For drug discovery and safety studies, mice have many advantages over other 
model organisms. Logistically, mice have a short gestation period (approximately 20 
days) and reach adulthood quickly3, reducing the cost of conducting studies in mice 
models over other mammalian options. Early identification of therapies that will fail 
testing in higher-level animals or clinical trials lowers the over-all cost of drug 
development. For these reasons, and others, 95% of all in vivo studies use mice2. 
 The utility of mice as a relevant platform is limited for understanding and 
predicting human responses to therapy regarding toxicology and/or disease progression4,5. 
In a large study comparing human and animal drug toxicities, rodent models (including 
mice) were only found to accurately predict human drug toxicity in 43% of cases6. 
Because of this, the US Food and Drug Administration (FDA) requires testing of drugs in 
at least two species, one of which must be a non-rodent.  Even with this stipulation, 
animal models were only accurate in 71% of cases6.  Thus, the safety of drugs cannot be 
fully assessed and significant risk is transferred to human patients during clinical trials, 
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which can result in serious consequences including death6,7. Although animal models 
share many characteristics with humans, the species-specific differences and unexpected 
toxicity results based on these models motivate research into other model systems8–11.  
 
In vitro models – 2D culture systems  
While animal models represent the total complexity of living, multicellular 
organisms, a reductionist approach to creating models has been applied in developing 
systems for high-throughput drug discovery.  The simplest and most well-accepted 
platforms use two-dimensional (2D) cell cultures, where cells adhere to a flat surface 
(typically polystyrene or glass) and are maintained with nutrients and growth factors in a 
liquid bath12,13.  This is attractive as an efficient and scalable means of culturing cells for 
high-throughput applications, since many cell types readily adhere to and grow on the 
stiff 2D substrates and the cellular environment be easily controlled through the cell 
culture medium12.  Although these models excel in handling and experimental logistics, 
they often fail to recapitulate cell behavior accurately. For example, despite the 
increasing the number of potential anti-cancer agents available for testing, only 
approximately 10% of compounds successfully progress to market14. Often (especially 
for anti-tumor therapies), these drugs fail late in clinical trials (particularly during phase 
III15,16) after considerable economic investment in the compound has been made. 
 There are many reasons that these models are not predictive, some of which are 
due to the substrate on which the cells grow. Tissues in the body have different stiffness 
and elastic characteristics (e.g. brain vs. bone), so it is unsurprising that cells can detect 
these differences and respond.  Using polyacrylamide gels as a substrate, Engler et al. 
found that the elastic modulus of the substrate could determine lineage selection for 
mesenchymal stem cells17.  
The substrate surface also affects cell behavior.  Tissues in the body are highly 
organized, with complex, 3D organization of cells and surrounding matrix proteins.  
Conventional 2D culture easily supports growth of cells in monolayers, and can be 
modified with micropatterning (via cell-adhesive islands18, microwells19, and 
micropillars20) to control cell shape and organization from the substrate surface.  
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However, modifications to the substrate surface cannot provide ECM interactions on all 
surfaces of the cell, inducing unnatural apical-basal polarization in cells and ultimately 
altering how the cells move and respond to their environment21. 
This work highlights the importance of choosing materials that mimic the in vivo 
environment, and thus substrate characteristics and geometries that promote 
physiologically-relevant behavior should be a design consideration for in vitro platform 
development. This has been recognized by both the Federal Drug Administration (FDA) 
and its European counterpart to push for in vitro organ models that better recapitulate 
human physiology and pathology4,5.   
 
In vitro models – Spheroids  
 To remove artifacts from stiff substrate interactions, protocols have been 
optimized for culturing cells as self-assembled aggregates – termed “spheroids” – without 
any direct substrate interactions.  To generate spheroids, a suspension of cells is 
distributed (usually as hanging drops22–25 or onto micropatterned low-adhesion 
surfaces22,26) and cells collect via gravity to create aggregates stabilized by cell-cell 
interactions. These protocols are highly reproducible, scalable, and are compatible with 
automated liquid handling systems, making spheroids a more attractive option than the 
2D predecessors. 
Although cells in spheroids produce some ECM components27, this method of 
culturing cells overall lacks 3D ECM interactions.  Additionally, the ratio of ECM to 
cells in spheroids is lower than is found in most tissues, adding bias to cell-cell contacts.  
For the purposes of mimicking ECM remodeling – a process important in the 
development of cancer28–30, fibrosis28,31,32, and autoimmune disease31,33,34 – spheroids are 
not the ideal model system.  Thus, there is also a need for platforms that enable 
incorporation of 3D ECM interactions.  
 
In vitro models – hydrogel culture systems 
In order to study cells in a more physiologically relevant 3D environment, 
methods and biocompatible materials for encapsulating cells in these biocompatible 
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materials have been developed. Three-dimensional culture models with protein-based 
scaffolds are better suited than synthetic options for studying cell-matrix interactions35,36 
and focal adhesion function37, and have been shown to be better predictors of drug safety 
and efficacy than 2D models38–43.  Moreover, 3D tissue models can capture the complex 
interplay between drugs, cell mechanics, and matrix interactions.  
One of the most common ECM-based material choices for 3D tissue experiments 
is collagen, which is the most abundant fibrous protein in the body comprising 30% of 
the total protein mass44,45, and which represents a non-inflammatory and hydrolysable 
environment46–48. Fabrication of 3D collagen models is typically in the form of relatively 
large (~mm in diameter) bulk gels, and cells are often grown in or on the gels to study 
cell function.  The readouts from 3D collagen hydrogel experiments vary based on 
application, but typical metrics include viability49,50, morphology50, protein expression 
via immunofluorescence or immunoprecipitation51, and cell contraction52–56.  
These 3D models are critical for studying cell-matrix interactions in a 3D 
environment in vitro, but fabrication of large-scale hydrogels is labor and time 
intensive57, the gels have significant diffusion limitations for nutrients and signaling 
molecules57, and they are difficult and cumbersome to analyze. Because of this, in vitro 
experiments in bulk gels are often limited to small sample sizes. Additionally, 
quantification within bulk gels could be more extensive, but the large geometry of these 
tissues can make complete visualization time consuming and often cannot be completed 
without physically altering the gel, making long-term studies with intermediate time 
points difficult to conduct58–60. Thus, there is a need for 3D ECM-based in vitro 
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Chapter 2: Microtissues as an improved in vitro model system 
This chapter contains material from “Rapid generation of collagen-based 
microtissues to study cell–matrix interactions” by Alexandra L. Crampton*, Marie-Elena 
Brett*, and David K. Wood. Technology, The Journal, volume 4, issue 2, pages 80-97, 




To answer this unmet need for scalable 3D culture systems, we aimed to develop 
an efficient system for high-throughput, 3D, ECM-based cell culture.  Leveraging 
microfluidic technology, we have alleviated several drawbacks of large hydrogels by 
miniaturizing the tissues (~14 nL in volume), transforming this tissue-engineering 
standard into an easy-to-use, high-throughput (>20,000 tissues/hour) platform with novel 
biological applications and enhanced statistical power. We have demonstrated that this 
microtissue platform can be used to efficiently perform standard in vitro measurements 
(e.g. collagen compaction, endothelial permeability).  We are now exploring applications 
aiming to improve the drug discovery pipeline (specifically, creating an improved human 
liver model for toxicology studies).  Because the microtissues are small and therefore 
require fewer cells per assay, we are also excited by the possibility of using these 3D cell 
culture modules to examine patient samples. In the future, we will aim to use these in 
vitro tissue mimics to accurately test several treatment regimens and assess primary 
effects (e.g. on a tumor sample) and secondary effects (e.g. liver toxicity).  
 
Collagen Microtissue Fabrication Protocol 
One way to overcome diffusion and throughput limitations in 3D tissue culture is 
to miniaturize the hydrogel scaffold. The advantages of miniaturized tissue models, or 
“microtissues,” that are only 25-300 µm in diameter include short diffusion times for 
nutrients and signaling molecules, enabling high cell viability through the tissue and 
rapid cell-cell communication across the entire gel.  The small length-scale additionally 
facilitates high-throughput imaging and analysis with automated methods. For these 
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reasons, several groups have developed methods to generate miniaturized gels by 
dispensing small volumes onto a surface61–64, polymerizing collagen in small tubing and 
extracting collagen modules65, or using agitation to create polydisperse collagen-in-oil 
emulsions66.  
An alternative option for partitioning the collagen solution is with droplet 
microfluidics, as liquids can be partitioned quickly, consistently, and with minimal 
human intervention.  Moreover, the resulting emulsions are monodisperse67,68, making 
this technology particularly useful for producing consistent replicates for screening 
applications.  To generate droplets, oil and aqueous solutions are introduced to a 
microfluidic device, and the relative flow rates, viscosities, and device geometry 
determine the volume of the aqueous compartments69.  
Droplet generators have a historic use in tissue engineering applications.  Most of 
these studies encapsulate live cells in rapidly-gelled, photo-polymerized PEG hydrogels, 
and is amendable to droplet-based studies70,71. PEG is biocompatible, quick to 
polymerize, and can be functionalized with protein motifs that permit cell interactions72–
75. However, even with these protein modifications, these gels are ill-suited for studies 
involving ECM remodeling and cell movement because (1) the pore size of the gels is 
significantly smaller than natural ECM 76,77 and (2) the cells cannot adhere to the majority 
of the matrix components (as cells only interact with the protein motifs of the hydrogel). 
Thus for our application, we directed our efforts on natural ECM as our biomaterial of 
choice for microtissue fabrication.                                                                                                           
Collagen is the most abundant fibrillar protein in the body44,45 and provides a non-
inflammatory and hydrolysable microenvironment46–48, motivating us to use this material 
as the base of our microtissues.  Collagen I hydrogels are thermally polymerized, 
meaning the compartmentalization into microtissues needs to be completed while 
collagen remains aqueous, but the polymerization must occur before the microtissues 
coalesce into a large hydrogel. Other groups have complicated and/or multilayer devices 
to complete this polymerization in the microfluidic device78,79 that greatly increase 
difficulty of device fabrication, reduce accessibility of the technology, and increase 
failure modes. Inspired by simpler microfluidic chip designs for droplet fabrication80, we 
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planned an easy-to-use protocol to generate and culture collagen microtissues with a 
single-layer microfluidic device (Figure 2.1). Microfluidic devices are first chilled in a 
4ºC cold room and all droplet generation is completed at 4ºC. We will then collect these 
microtissues and polymerize the constructs outside the microfluidic device at 25ºC -37ºC.  
Once this fabrication protocol was optimized, we aimed to validate cell viability 
and function, and then use our unique material and geometric properties to create novel 
readouts of cell function in the miniaturized tissues.  We anticipated that protein-based 
microtissues could be the ideal 3D culture platform to study processes that utilize cell-
fiber interaction, such as cell adhesion and matrix remodeling, using straightforward 
methods that are compatible with high-throughput studies. In the following chapters, we 
will demonstrate the function of our platform as a fabrication method for cell-laden 
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Figure 2.1: Microtissue fabrication  
Cells were mixed into collagen and the solution was perfused into a microfluidic droplet 
generator. Fluorocarbon oil was perfused into the device to produce droplets. Droplet 
formation was performed at 4°C, then droplets were incubated at 37°C for 30 minutes. 
Oil was aspirated and droplets were resuspended in media and transferred to a 
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Chapter 3: Demonstration of feasibility and biocompatibility of microtissue workflow 
This chapter contains material from “Rapid generation of collagen-based 
microtissues to study cell–matrix interactions” by Alexandra L. Crampton*, Marie-Elena 
Brett*, and David K. Wood. Technology, The Journal, volume 4, issue 2, pages 80-97, 




Our goal for this work was to create a method for studying cell-matrix 
interactions in a more physiologically relevant 3D protein-based hydrogel tissue that 
could be scaled up to perform large-scale screens, study cell-matrix interactions on a 
population basis, or be remodeled by cells to build larger tissues. We developed an easy-
to-use method that leverages microfluidic droplet technology to miniaturize protein-based 
hydrogels and thus extend their application to high-throughput studies.  With this method, 
we fabricated cell-laden collagen hydrogels that are uniform in size, without complicated 
on-chip temperature control79. This affords the ability to use a simple protocol to create 
tens of thousands of identical cell-laden microtissues within a few hours and subject them 
to a wide variety of experimental conditions.  The increased production rate and uniform 
distribution of the collagen hydrogel droplets created with our device lends itself to 
quantification of cell-matrix interactions and matrix remodeling of cells on a large-scale 
microtissue-by-microtissue basis. Here, we describe our method and demonstrate the 
applicability of these protein-based microtissues for studying cell-matrix interactions. In 
this study, we demonstrate that (i) cells can interact with the 3D environment both while 
encapsulated or while interacting only with the surface of the microtissues, (ii) 
encapsulated cells are highly viable, and (iii) our platform facilitates micropatterned co-
culture.   
 
Innovation 
The technology presented in this chapter combines rapid droplet generation with 
global temperature control to create protein-based microtissues with an easy-to-use 
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microfluidic device. The microtissues formed with our platform are composed solely of 
extracellular matrix protein, uniform in size, and generated rapidly (>20,000/hour), 
which facilitates large-scale experiments with large numbers of treatment groups and 
hundreds of replicates. Our method uses only common laboratory temperatures (4°C and 
37°C) and requires no on-chip temperature control or temperature gradients, which means 
this technology can be easily disseminated and integrated within a high-throughput 
pipeline.  Additionally, we demonstrate novel patterning of cell co-cultures within and 




Microfluidic devices were utilized to generate and image microtissues. We 
fabricated a set of microfluidic devices consisting of a single emulsion droplet generator 
with a 150 µm nozzle and a microtissue capture device used for imaging, Figure 2.1. To 
fabricate these devices, we employed soft photolithography of PDMS procedures similar 
to those described previously70,71,81–83. 
Cell culture.  
Before encapsulation or adhesion all cells were cultured in tissue treated cell 
culture flasks and incubated at 37°C with 5% CO2. Endothelial cells were cultured in 
tissue culture flasks pre-coated with 0.05% collagen. To dissociate cells, flasks were 
aspirated and washed with HBSS (Gibco), then trypsinized with 0.05% porcine trypsin 
(Gibco). Media was then added to trypsinized cells and the cell solution was pelleted. 
Cells were resuspended in serum-free media and were counted using an automated 
hemocytometer and Trypan Blue (Sigma) to discern viability. Upon counting, cells were 
added to a solution of unpolymerized collagen and buffered to the desired final 
concentration. In the case of cells that were used to coat collagen droplets or bulk gels, 
cells were added to media containing polymerized collagen droplets or bulk gels as 
described below. 
 
Microtissue construction.  
 
	
 11  
Microtissues consisted of collagen I, with or without cells encapsulated within the 
hydrogel and/or adhered to the hydrogel surface. Microtissue fabrication began with 
adding either HEPES pH 7 or PBS buffer to high concentration rat tail collagen, type I 
(Beckton Dixon), to a final concentration of 2, 4, or 6 mg/mL on ice. The pH of the 
collagen cell solution was then adjusted to 7.4-7.6 pH using 1N NaOH. The solution of 2-
6 mg/mL collagen and 8 x 105 cells/mL for cancer cells or 2 x 106 cells/mL for 
fibroblasts was perfused into the droplet generator inlet at 150 µL/hr, and Fluorocarbon 
oil (FC-40, Sigma) with 2% EA surfactant was perfused at 1000 µL/hr to produce 
droplets71, Figure 2.1.  Droplets were formed at 4°C and polymerized for 30 minutes in a 
37°C incubator. The final fibroblast concentration in polymerized microtissues (~1.25 x 
106 cells/mL) was lower than the initial concentration in the unpolymerized collagen 
solution due to settling in the syringe coupled to the microfluidic flow-focusing device.  
Microtissues were collected, washed, and re-suspended in media. Microtissues were then 
transferred to the droplet capture device, imaged, and incubated for 24-72 hours.  
 
Dispersity measurement.  
To measure size range of microtissues, oil was aspirated and polymerized 
microtissues containing 1 µm polystyrene beads were resuspended in appropriate 
media. Polystyrene beads were used to enhance the image contrast under brightfield 
microscopy.  Microtissues were then transferred to a capture device for imaging, Figure 
2.1.  An automated image analysis tool was written in ImageJ84 and used to measure the 
diameter of each microtissue. 
 
Viability assessment.  
To determine the viability of encapsulated cells, microtissues were stained with 
500 nM propidium iodide and 0.01 mg/mL Hoechst. Microtissues containing cells were 
resuspended in serum-free media and stained immediately after polymerization to 
determine viability after microtissue fabrication. Additionally, microtissues coated with 
fibroblasts (NIH 3T3), breast cancer epithelial cells (SUM 149), or endothelial cells 
(HUVEC); were stained with 500 nM propidium iodide and 0.01 mg/mL Hoechst to 
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determine the viability of cells on the outside of microtissues. To assess prolonged 
viability, microtissues were placed in capture devices with various serum concentrations 
(0, 1, or 10%) and incubated at 37°C and 5% CO2 for 24-72 hours before staining and 
imaging several focal planes through the thickness of the microtissues.  To quantify 
viability, maximum projections for each fluorescence channel were calculated using the 
Extended Depth Of Field plugin in ImageJ85. The total cells (from Hoechst) and the 
number of dead cells (from propidium iodide) were recorded on a microtissue-by-
microtissue basis and used to calculate the viability.  
 
Microtissue co-culture.  
Co-culture was achieved by coating cell-laden microtissues with a second cell 
type.  Triple negative breast cancer cells expressing green fluorescent protein (MDA-
MB-231eGFP) were encapsulated in 6 mg/mL collagen microtissues.  After 
polymerization, microtissues were cultured in ultra-low adhesion plates for up to 5 days 
to allow encapsulated cells time to spread out within microtissues. Approximately 2 x 106 
cells of a second cell type were incubated with an average of 500 microtissues overnight 
in ultra-low-adhesion plates.  After incubation, coated droplets were transferred to droplet 
capture devices and imaged within 24 hours.  When coating with human umbilical vein 
endothelial cells (HUVECs), cells were stained with 5 µM Calcien Deep Red (AAT 
Bioquest Inc.) to facilitate visualization. MDA-MB-231eGFP microtissues were 
alternatively coated with SUM 149 (a generous gift from James McCarthy), transfected 
with mCherry (Clontech) (SUM 149mCherry) for enhanced visualization.   
 
Results 
Microtissue fabrication.   
A microfluidic flow-focusing device was used to generate collagen pre-polymer 
droplets suspended in an immiscible, fluoropolymer oil (Figure 2.1). This process was 
conducted at 4°C to ensure that the collagen solution would not polymerize before being 
formed into microtissues.  The liquid collagen droplets were then collected and incubated 
at 37°C to facilitate polymerization into microtissue gels, after which polymerized 
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microtissues were separated from the oil phase.  We found that microtissues needed 
between 15 and 30 minutes of 37°C incubation to polymerize fully (Figures 3.1a and 
3.2a).  This method generates nanoliter-volume polymerized collagen microtissues very 
rapidly (>20,000 microtissues/hour), and they can be generated with or without 
encapsulated cells.  
 
Microtissue characterization.  
One of the primary advantages of using microfluidic flow focusing is the low 
polydispersity among the droplets. To quantify the polydispersity in our microtissue 
populations, we collected polymerized microtissues and quantified their diameters from 
images similar to those in Figure 3.1a.  For a large population of microtissues (n = 591), a 
histogram of the diameters was created (Figure 3.1b).  We observed a narrow distribution 
of size with a coefficient of variance ranging from 8.4% - 13.9%. This size variance is 
sufficiently small that it does not interfere with subsequent analyses. Throughout our 
trial, we found that 1.2% - 1.8% of droplets coalesced into doublets or triplets before 
polymerization.  This population, however, did not influence later analysis as the 
geometry of the droplet capture devices excluded these larger microtissues based on size. 
 
Viability of encapsulated cells.  
High cell viability is imperative for conducting biological assays with any in vitro 
platform. As shown in Figure 3.2, we quantified the viability of MDA-MB-231eGFP 
breast mammary carcinoma cells encapsulated within our microtissues. Cell viability was 
quantified immediately after microtissue polymerization, and after 72 hours of incubation 
with various serum concentrations. We observed that the viability of encapsulated MDA-
MB-231eGFP cells were consistent throughout the experiment period. The initial 
viability was high (greater than 90%) (Figure 3.2c), and the extended viability of these 
cells fluctuated at most by 6% at the end of the 72-hour incubation.   
 
Matrix interactions.  
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To demonstrate our ability to study cell-matrix interactions within our protein-
based microtissues, we studied the morphology of breast carcinoma cells, and we 
quantified the ability of fibroblasts to contract microtissues. As shown in Figure 3.2a, 
over 72 hours in culture, we observed that encapsulated MDA-MB-231eGFP cells were 
able to spread out and send projections throughout the collagen matrix. This change in 
morphology indicates that these cancer cells can to adhere and interact with the 3D 
environment of the collagen microtissue. 
 
Coating microtissues with cells 
 Another method to incorporate cells with the microtissues is to coat the surface of 
the constructs.  We fabricated acellular microtissues with fluorescent beads to denote the 
microtissue borders.  A single cell suspension of fibroblasts was collected and cells were 
added to a microfluidic droplet capture device along with collagen microtissues.  After 24 
hours of culture, we observe that fibroblasts adhere to the surface of the microtissue 
constructs (Figure 3.3).  We observe that cells added to the surface of constructs 
remained on the surface and did not migrate towards the center of the microtissues within 
the first 24 hours (Figure 3.3). 
 
Microtissue co-culture.  
The small size of the microtissues (~100-300 µm) enables a novel method for 
patterning multiple cell types in 3D.  Here, we demonstrate that we can separately 
encapsulate one cell type within the microtissues while coating the microtissue surface 
with a separate cell type (Figure 3.4).  To illustrate this versatility, we first encapsulated 
MDA-MB-231eGFP cells within 6 mg/mL collagen droplets. We then seeded calcein-
stained HUVECs or SUM 149mCherry (Figure 3.4) cells on the outside of each droplet 
as described in the methods. After overnight incubation, microtissues were stained with 
Hoechst and imaged on a confocal microscope. Figure 3.4a depicts where slices for 
subsequent images were located within the microtissue and Figure 3.4b shows DIC 
images taken at these locations within the droplet. In Figure 3.4c, Hoechst staining of cell 
nuclei demonstrates that cells cover the microtissue and Figure 3.4d shows that the 
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second cell type adhered to the outer surface of microtissues. Figure 3.4e demonstrates 
that the majority of MDA-MB-231eGFP cells are found within the microtissue and not 
on the surface. An overlay of each color channel in both the top and middle of the 
microtissue demonstrates were able to conduct co-cultures with our microtissues. We 
quantified the viability of cells coating the surface of the microtissues, which was 72% 
for endothelial cells (HUVECs) and 81% for breast carcinoma cells, similar to numbers 
obtained for fibroblasts.  
 
Discussion  
Here we present an easy-to-use method to rapidly fabricate collagen microtissues 
using a microfluidic flow-focusing device. With our method, we produce monodisperse 
collagen microtissues.  These microtissues are composed entirely of natural ECM, 
making them an interesting tool to study cell-matrix interactions and matrix remodeling 
in a high-throughput manner.  Additionally, since we can produce large quantities of 
microtissues (20,000/hour), the sample sizes in our experiments (n>>25) can be much 
larger than typical studies with collagen hydrogels (n<=5), supporting robust statistical 
analysis across experimental conditions.   
After optimizing the fabrication process, we examined the cell behavior to ensure 
high cell viability and expected cell interactions with the collagen matrix.  We found the 
cells had high cell viability in our constructs, and that cells spread out and explored the 
collagen matrix with long protrusions shortly after encapsulation. This demonstrates that 
the cells do not only tolerate our fabrication method, but that they thrive in this 3D 
environment.   
Finally, we explored controlling the placement of cells in our constructs.  We 
demonstrated that we could coat just the surface of the microtissues, or use a combination 
of encapsulating and surface-coating to co-culture cells.  This micropatterning of cells in 
our constructs creates exciting opportunities to examine cell-cell interactions in a 3D 
environment in future studies.   
With this validation of our platform, we began to explore novel readouts and 
applications that our platform is uniquely suited to address.  The following chapters 
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describe these assays and applications in detail, beginning first with the adaptation of a 
standard assay to assess fibroblast contractility in 3D.  
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Figure 3.1 Polymerized collagen droplets 
 (a) Brightfield image of collagen droplets. Scale bar 300 µm. (b) Histogram of droplet diameters 
with mean diameter of 182 µm (n=591) and a CV of 8.4% with a smooth histogram (kernel 
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Figure 3.2. Collagen polymerization and cancer cell viability 
(a) Collagen droplets were generated at 4°C and placed in a 37°C incubator. Aliquots of droplets 
were removed every 15 minutes and imaged to determine polymerization. (b) Images of MDA-
MD-231eGFP immediately following microtissue resuspension in media, and after 3 days in of 
culture. Scale bar denotes 100 µm. (c) MDA-MB-231eGFP cells were encapsulated in 6 mg/mL 
collagen microtissues.  The cell viability was assessed with propidium iodide/ Hoescht staining 
and quantified on a microtissue-by-microtissue basis.  The average microtissue viability is 
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Figure 3.3: Optical sectioning demonstrates surface coating of microtissues   
Acellular 6 mg/mL collagen constructs with 1 µm fluorescent beads (blue) were fabricated and 
collected in PBS.  NIH 3T3 cells were seeded on the surface of the microtissues in DMEM with 
10% FBS.  Constructs were cultured for 24 hours before staining with DRAQ5 to label the nuceli 
(magenta) and calcein AM to label the live cells (green).  With confocal imaging we examine 
optical sections near the top and middle of the constructs, demonstrating that surface-coated cells 








Figure 3.4: Cell seeding of microtissues 
Cells were encapsulated and / or seeded on the exterior of collagen hydrogels and imaged using a 
confocal microscope. (a) Schematic of where image slices are located within the droplet. (b) 
mCherry florescence from SUM 149 mCherry cells or Deep Red Calcein staining of endothelial 
cells. (c) GFP expression of encapsulated MDA-MB-231eGFP cells. (d) All fluorescent channels 
over-laid. Scale bar is 50 µm. 
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Chapter 4: Application – A miniaturized contraction assay 
This chapter contains material from “Rapid generation of collagen-based 
microtissues to study cell–matrix interactions” by Alexandra L. Crampton*, Marie-Elena 
Brett*, and David K. Wood. Technology, The Journal, volume 4, issue 2, pages 80-97, 




There is an unanswered demand for physiologically relevant model systems that 
improve drug development and depart from traditional cell culture to incorporate cell-
ECM interactions and recapitulate ECM remodeling. Three-dimensional cell culture has 
begun replacing 2D model systems as they are better mimics of the in vivo environment. 
By reducing systemic artifacts due to substrate geometry12,86,87, stiffness88–91, and 
availability of cell-ECM interactions92–94, these 3D platforms show increased predictive 
power and improved functional utility when screening for therapeutic efficacy. 
Furthermore, due to increased interest in studying tissue-level diseases that involve cell-
ECM interactions and ECM remodeling (development of cancer28–30, fibrosis28,31,32, and 
autoimmune disease31,33,34), there is a need for improved 3D cell culture tools and 
workflows that support cell-ECM interactions and remodeling.  
The current gold-standard in vitro model system of 3D wound healing, 
remodeling, and contraction is the contraction assay, invented by Bell et al. in 197995.  In 
this assay, large cell-laden collagen I gels are polymerized and cells are cultured within 
the hydrogels.  As cells remodel the matrix, the hydrogel contracts and changes in the 
overall tissue geometry can be quantified.  The rate and extent of matrix contraction and 
remodeling in these contraction assays has been further studied, revealing the influence 
of co-culture and ECM proteins in these 3D culture systems96–98.  The mechanical 
properties of the gel also affect cell contractility, as not only gel density, but also the 
loading state of the gel (attached to the sides of the container, or free-floating) affects the 
amount of gel contraction.   
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These variations of the contraction assay have several advantages – they provide a 
3D environment for the cells, the procedures are compatible with cell viability and also 
cell function, and the systems are highly tunable (as far as gel concentration and exact 
ECM composition). There are some limitations for these assays, though, because of the 
large size of the hydrogels.  Collagen gels for contraction assays are typically cast in 24-
well or 6-well plates, requiring 0.5-2 mL of collagen solution per replicate.  These large 
volumes are expensive in terms of reagent use (especially for high concentration gels), 
but also limit the number of replicates for experiments as the number of cells required 
scales linearly with the volume of the gels.  For studies interested in large-scale screens 
or using small patient samples (e.g. tumor biopsies), these large volumes are prohibitive.  
Additionally, the large volumes mean large geometries, which introduces an issue with 
diffusion into the gel of oxygen and nutrients, and also challenges with imaging as the 
tissues are thick (>1 mm).  To use a 3D contraction assay for high-throughput screening, 
this issue of the large volume, large cell requirements, and large geometries needs to be 
addressed.   
Our objective for this study was to create a method for studying cell-matrix 
interactions in a physiologically relevant 3D protein-based tissue construct that could be 
scaled up to perform large-scale screens and study cell-matrix interactions on a 
population basis. We have previously (Chapter 3) developed an easy-to-use method to 
miniaturize protein-based tissue constructs that maintains the 3D in vitro environment, 
while alleviating several obstacles associated with larger avascular tissue constructs. In 
this study, we demonstrate – for the first time to our knowledge – that microtissues on 
this size scale (~200 µm) can be used to quantify cell contractility.  This assay highlights 
the value of miniaturization, as our large population sizes support robust statistical 
analysis.  This versatile platform should facilitate large-scale screens in 3D in vitro 
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Before encapsulation or adhesion all cells were cultured in tissue treated cell culture 
flasks and incubated at 37°C with 5% CO2. To dissociate cells, flasks were aspirated and 
washed with HBSS (Gibco), then trypsinized with 0.05% porcine trypsin (Gibco). Media 
was then added to trypsinized cells and the cell solution was pelleted. Cells were 
resuspended in serum-free media and were counted using an automated hemocytometer 
and Trypan Blue (Sigma) to discern viability. Upon counting, cells were added to a 
solution of unpolymerized collagen and buffer to the desired final concentration. In the 
case of cells that were used to coat collagen droplets or bulk gels, cells were added to 
media containing polymerized collagen droplets or bulk gels as described below 
 
Microtissues for Contraction Assay 
Microtissues were fabricated following the protocol described in Chapter 3. To 
measure contraction of microtissues coated with fibroblasts, 0.05% 1 µm diameter FITC 
beads were encapsulated in collagen to allow visualization of microtissue borders.  After 
polymerization, droplets were resuspended in PBS and stored at 4°C. Droplet capture 
devices were loaded with droplets and ~250,000 NIH-3T3 fibroblasts in either serum-free 
or 10% serum growth medium.  To isolate the change in shape due only to cell-ECM 
interactions, droplet capture devices without cells were also loaded and used to measure 
the initial size of the droplets, as cells began contracting microtissues immediately upon 
addition to the device and introducing cells after time zero imaging deformed the 
microtissues. Droplet capture devices were imaged immediately after the addition of 
cells, as well as after 24 hours of incubation.   
 
Bulk Gel Fabrication and Analysis 
To fabricate collagen bulk gels for comparison, collagen of varying concentration 
(2, 4, or 6 mg/mL) was mixed with buffer on ice and 1N NaOH was added until collagen 
reached a pH within the range of 7.4-7.6.  A single cell suspension was added to the 
collagen before polymerization. Bulk gel fabrication was similar to microtissue 
fabrication, except the volume required to produce bulk gels was significantly larger 
(with each experiment requiring ~1.5 mL solution rather than 400 µL to create two orders 
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of magnitude more microtissues).  Cell-laden bulk gels were cast in 96 well plates and 
allowed to polymerize for 30 minutes.  Serum-free media was then added on top of the 
gels before they were carefully floated and transferred to a 24 well plate.  Gels were 
imaged before adding serum to any of the serum-containing conditions to prevent any 
serum-induced contraction in initial measurements.  Gels were incubated for 24 hours 
and imaged again.  For each experiment, acellular gels were included as negative 
controls.  Each trial was conducted in triplicate and repeated three times.  Area 
measurements were made identically to trials of corresponding microtissues (gels were 
outlined and area was quantified on a gel-by-gel basis).  
To measure contraction of bulk gels coated with fibroblasts, collagen solutions of 
various collagen concentration with 0.05% 1 µm FITC beads were made similarly to 
microtissues, but with increased volume.  Acellular gels were cast in 96-well plates and 
polymerized for 30 minutes before gels were floated and transferred to 24 well plates.  
Gels were imaged before adding ~500,000 fibroblasts/mL media in the plate.  After 24 
hours incubation, gels were imaged again and the area for both time points was measured.  
Experiments were repeated three times in triplicate.   
 
Quantification of Cell Contraction 
 Brightfield images were used to identify the area of 2, 4, or 6 mg/mL collagen 
microtissues containing NIH-3T3 fibroblasts immediately after microtissue 
polymerization and after 24-hour incubation with or without 10% serum treatment.  To 
quantify contraction, each droplet was outlined by hand in a single-blind analysis, and the 
area within the outline was measured and recorded.  To measure contraction in cell-free 
microtissues coated with NIH-3T3 fibroblasts, emission from encapsulated fluorescent 
beads was used to measure the projected area of the droplets, thus excluding any bias in 
size based on the number or diameter of cells attached to the droplets. An automated 
image analysis tool was written in ImageJ and used to measure the diameter of each 
microtissue defined by encapsulated FITC beads. The relative change in area between 
experimental conditions was compared. The coefficient of variation (CV) was determined 
from these measurements. 
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Statistical Analysis 
The relative difference in microtissue area (contraction) was compared using t-
tests or ANOVA with Bonferroni correction.  Experimental replicates were analyzed 
separately, and p-values <0.05 were considered statistically significant.   
 
Results 
To quantify cell-matrix interactions, we measured contraction of the collagen 
microtissues by fibroblasts (Figure 4.1a). We constructed hydrogel droplets of varying 
initial collagen concentrations (2-6 mg/mL) and either encapsulated or coated hydrogels 
with NIH-3T3 fibroblasts to quantify contraction in two ways with our microtissues. For 
these experiments, we encapsulated the cells inside the tissues or coated the tissues with 
cells under serum-free conditions, followed by 24-hour incubation with serum to induce 
contractility. Figures 4.2a-c show images of individual microtissues coated with 
fibroblasts before and after treatment with serum at three different initial collagen 
concentrations and controls not treated with serum. The images clearly show that cells 
incubated with serum were able to contract the microtissues more than their serum-free 
counterparts. The images also reveal that the amount of microtissue contraction decreased 
as initial collagen concentration increased. As shown in Figure 4.2e,f, in which projected 
microtissue area is quantified, these trends are consistent for the case of cells 
encapsulated within or coated on the microtissues. The largest contraction was observed 
for 2 mg/mL initial collagen concentration tissues, in which the average microtissue area 
decreased by 23% and 40% for encapsulated and coated cells, respectively. The smallest 
contraction was observed for 6 mg/mL collagen tissues, in which the average area 
decreased by 10% for coated cells and no significant change was seen with encapsulated 
cells. We note that the collagen concentrations reported are only the initial concentration, 
and the concentration is increasing as the cells contract the microtissues, which has been 
reported previously99. 
To compare these results with traditional assays, we performed identical 
experiments on large gel constructs (~6 mm diameter), and the results are shown in 
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Figure 4.2e,f. The observed trends for bulk gels were the same as for microtissues as well 
as previously published results53–55,95.  Thus our microtissue platform is able to 
recapitulate the results from the standard bulk gel assays while simultaneously decreasing 
labor and time for gel fabrication, simplifying imaging and analysis, and improving the 
statistical robustness of the results. 
We also tested the hypothesis that the trends in cell contractility as a function of 
initial collagen concentrations were due to differences in cell viability. We quantified 
fibroblast viability immediately after polymerization and after 24 hours incubation, to 
mimic the culture conditions of the contraction experiments. As shown in Figure 4.1b, 
fibroblast viability was initially high in all conditions (79%-95%), and fluctuations in 
viability were not statistically significant over the 24-hour incubation period. Because 
cell viability was consistent throughout the experimentation period (Figure 4f), 
differences in contraction among initial collagen concentrations were not attributed to 
cell death. Instead, we attribute these trends to inhibition of contraction in the higher 
concentration collagen matrices. We also attempted to quantify cell viability for cells 
encapsulated in bulk gels, but the increased diffusion time for the dyes due to the larger 
size of bulk gels limited our ability to uniformly stain the gels before cell death was 
induced by the dyes. Overall, the combination of high cell viability in the microtissue 
culture and the ability of cells to contract the collagen matrices support the goal of this 
platform to be used to study cell-matrix interactions. 
 A specific application of this type of assay would be to screen compounds and 
assess changes in contractility in response to treatments.  As a proof-of-concept, we 
tested our platform with Fasudil (a Rho-kinase inhibitor) and Blebbistatin (a Myosin II 
inhibitor) to determine if our assay could be used to detect inhibitors of compaction.  We 
fabricated acellular 4 mg/mL collagen microtissues containing 1 µm fluorescent beads, 
and coated these tissues with highly contractile human lung fibroblasts (HLF 240).  
Inhibitors and cells were both added at t=0, and constructs were observed at several 
timepoints for 24 hours (Figure 4.3).  We found that for microtissues treated with Fasudil 
(Figure 4.3a), statistically significant inhibition of compaction (p<0.05) was apparent 
after 2 hours and remained significant after 24 hours (p<0.0001), with the final difference 
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in compaction being 32.0% +/- 5.2%.  For the Blebbistatin group (Figure 4.3b), very 
statistically significant inhibition of compaction was observed after 24 hours (p<0.0001), 
with the final difference in compaction of 23.6% +/- 6.5%.  The large dynamic range of 
this selected screen is promising for the use of this assay for larger-scale screening for 
discovery of inhibitors of contraction and matrix remodeling. 
 
Discussion 
Our goal in the development of this platform was to overcome the limitations of 
typical bulk gel assays and make 3D tissue culture more amenable to high-throughput 
screening applications. These protein-based microtissues are well suited to high-
throughput screening because they can be rapidly generated, analysis can be automated, 
and comparisons can be made across uniform populations. Further, the miniaturization of 
the gels causes no limitations in the potential applications, as the cells can fully interact 
with and even remodel the matrix. We have demonstrated that with our method, 
encapsulated cell viability is high (80-98%) and is maintained throughout extended 
incubation periods, and that behaviors observed in bulk gels (e.g. contraction, spreading) 
are also observed in our smaller-scale hydrogels. A major advance over bulk gel 
experiments is that the large numbers of microtissues lead to high statistical power in the 
results.  Moreover, because our growth conditions are compatible with standard cell 
culture equipment (e.g. multi-well plates), this method could be scaled up even further 
and be integrated with automated liquid handling systems and automated imaging 
platforms. We demonstrate that cancer cells, endothelial cells, and fibroblasts can interact 
with our collagen microtissues – both while encapsulated and while coating the surface of 
the droplets – which allows for novel co-culture applications where the physical and 
chemical interactions between cell types can be controlled. Overall, this platform 
recapitulates the functions of traditional protein-based bulk gels but extends application 
to high-throughput studies and opens up new possibilities for interrogating cell-cell and 
cell-matrix interactions. 
We demonstrate that we can quantify cell-matrix interactions in our microtissues, 
including cell spreading and contractility, across large numbers of microtissues, which 
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lends itself to high-throughput studies and robust statistical analysis. We use serum to 
induce contraction as this phenomenon has been widely observed99–102, with 
lysophosphatidic acid and platelet-derived growth factor thought to be important serum 
components for inducing cell contraction100,102. Encapsulated carcinoma cells and 
fibroblasts were able to spread within the gels and engage the matrix, and encapsulated 
fibroblasts were able to significantly contract the microtissues when stimulated with 10% 
serum. We observed the highest level of gel contraction (25%) at the lowest collagen 
concentration (2 mg/mL), and the amount of contraction decreased as the collagen 
concentration increased, with no discernible contraction in the 6 mg/mL microtissues, 
which agrees with existing trends for bulk gel contraction assays53–55,95. These findings 
are also in line with bulk gel experiments performed in this study, demonstrating 
reproducibility of the results between our assay and the standard bulk gel assays. We 
verified that the differences observed in contraction between initial collagen 
concentrations was not due to cell death, as the viability of these microtissues was high 
and consistent throughout the observation period. We attribute the decrease in contraction 
in the higher concentration gels to the increased density of collagen fibers. Although the 
cells are viable and can interact with fibers in the higher density collagen microtissues, 
either the force exerted by the cells and/or the strength of the cell-matrix linkage is 
insufficient to generate matrix reorganization. This finding agrees with previous studies 
showing that tensional homeostasis in cells works over a limited stiffness range, where 
extremely soft substrates do not engage cytoskeletal reorganization and contractility, 
while extremely stiff substrates present mechanical forces that cannot be overcome by the 
cells103–106.  
Additionally, initial collagen concentration has been shown to affect both the rate 
and the total amount of contraction95,107. Previous studies show that fibroblasts 
encapsulated within a collagen matrix are able to contract a less dense matrix faster95. 
Although the rate of contraction and the difference in contraction rates between different 
matrix concentrations decrease over time, gels with a lower initial collagen concentration 
demonstrate increased overall contraction95,107. This suggests the initial matrix 
concentration itself is able to modulate the total amount of contraction107. Further study 
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of the underlying mechanism of this behavior shows that the viscoelastic properties of a 
collagen hydrogel are dependent on the initial collagen concentration108. This viscoelastic 
model, initially proposed by Moon and Tranquillo, suggests that cells are able to apply 
traction forces on the collagen network by pulling collagen fibrils into proximity using 
pseudopods108. The reduction in gel area measured is driven by these cell traction forces 
which are dependent on the viscoelastic properties of the collagen hydrogel and thus the 
initial collagen concentration108. To the authors’ knowledge, this is the first 
demonstration that individual microtissues with encapsulated fibroblasts can be used to 
quantify gel contraction, which is a gold standard for assessing fibroblast contractility 
and matrix reorganization53,95. 
The results from this study implicate the potential for microtissues composed 
solely of ECM proteins for high-throughput screening applications. One potential 
application of this platform is in the development of anti-fibrotic agents. It is widely 
known that fibroblast contraction of the extracellular matrix is highly relevant to 
increased fibrosis in diseases such as peritoneal fibrosis and that this contraction is 
mediated by RHO kinases109. Peritoneal fibrosis is common in long-term kidney dialysis 
patients, as peritoneal dialysis stimulates the production of TGF-β and TGF-β plays a 
fundamental role in fostering fibrosis110. One method to abrogate the development of 
fibrosis in dialysis patients is to inhibit RHO-kinase, and the RHO-kinase inhibitor 
Fausidil has been shown to diminish fibrosis clinically110. The development of such 
therapies, however, requires high-throughput screening for compounds that can inhibit 
contractility. Although such a screen would be time and cost prohibitive using bulk gels, 
it could easily be accomplished using this platform. Our system is capable of generating 2 
mg/mL collagen droplets at rates of >20,000 droplets per hour. Given the 0.354 
coefficient of variation for contractility in our 2 mg/mL collagen droplets, we would only 
need 25 microtissues in each treatment group to achieve a statistical power of more than 
80%. With 10 devices in parallel for 2 hours, we could test 12,000 unique compounds. 
Moreover, all of the tissues are batch polymerized and could be automatically dispensed 
and treated using robotic liquid handlers, thus allowing all treatment types, 
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concentrations, and controls to be performed in a relatively short period of time with high 
statistical power. 
These microtissues are also ideal for cancer drug discovery and high-throughput 
cancer biology. Using the same workflow as described above, this platform could be used 
to test the efficacy of small molecule therapeutics on tumor cell proliferation and 
viability. Alternatively, new therapeutic targets could be discovered using protein 
knockdown with RNA interference or gene editing.  Additionally, our microtissues have 
applicability outside the use as individual culture vessels; rather, our rapid generation 
method could be used to enhance existing methods to 3D print cell-laden collagen 
tissues111, serving as the base for quick construction of increasing complex tissue 
constructs.  This could even include larger vascularized tissue constructs, which has 
applications in the study of cellular behavior in vitro as well as translational potential in 
regenerative medicine. Overall, this is a highly versatile platform for 3D cell culture that 
is engineered to facilitate quantitative studies of drugs, cellular interactions, and 
biological mechanisms in high-throughput applications. 
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Figure 4.1: Scaling down the contraction assay for collagen microtissues   
Traditional contraction assays use large volume hydrogels to assess cell contractility.  Cells can 
either be encapsulated in the hydrogel (not shown) or coated on the surface of an acellular 
hydrogel (a), both resulting in a decrease in gel volume and projected area.  Our scaled-down 
version of this assay (a) follows the same workflow, with the addition of encapsulated fluorescent 
beads to clearly distinguish the projected area of the microtissues.  This system is compatible with 
a wide range of cell types, and for this study we focus on fibroblasts as they are highly contractile 
cells.  We confirmed that NIH-3T3 cells in both the encapsulated and surface-coated 
configurations for all collagen concentrations and growth conditions used in this study are highly 
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Figure 4.2: Fibroblast contraction of collagen 
 (a-c) Fluorescent images of 2 mg/mL (a), 4 mg/mL (b), or 6 mg/mL (c) collagen microtissues 
containing 1 µm FITC beads and coated with NIH 3T3 fibroblasts. Microtissues with no cell 
coating, cell coating in serum-free media, and cell coating with media containing 10% serum 
were cultured for 24 hours. Scale bars 100 µm. (d) Changes in projected area for large droplet 
populations were measured and the population change in microtissue area is reported with 
standard error. Three experimental replicates were examined for each condition. For fibroblasts 
encapsulated in collagen droplets (d), the difference in contraction was statistically significant (p 
≤ 0.01) in 2 mg/mL trials, and for two of the three replicates the difference was very statistically 
significant (p<0.0001).  For all of the 4 mg/mL trials, the difference in contraction was 
statistically significant (p<0.05).  For the 6 mg/mL trials of encapsulated fibroblast microtissues, 
none of the differences in contraction were statistically significant. For all concentrations of 
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collagen of microtissues coated with fibroblasts (e), the difference in contraction was very 
statistically significant (p<0.0001) with n values of n = 51, 168, and 219 and n = 119, 73, and 229 
for trails of 2, 4, or 6 mg/mL microtissues in serum-free or 10% serum media respectively.  For 
Bulk gel examination (d,e) n =3 for each trail of coated and encapsulated fibroblasts, three 
individual trials were performed for each condition. + signifies that the data above was collected 
from trials containing microtissues, encapsulated fibroblasts, or 10% serum in media. Population 
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Figure 4.3: Fasudil and Blebbistatin inhibit compaction of microtissues.    
Fluorescent images of 4 mg/mL collagen microtissues containing 1 µm fluorescent blue beads 
and coated with HLF 240 fibroblasts in DMEM with 10% serum.  Microtissues were then treated 
with (a) 100 µM Fasudil or (b) 50 µM Blebbistatin with a DMSO vehicle control.  Representative 
images for each condition after 24 hours of treatment are displayed (scale bars = 200 µm).  
Changes in projected area for large droplet populations were quantified and the population 
change in microtissue area is reported with standard error.  For microtissues treated with Fasudil, 
statistically significant inhibition of compaction was apparent after 2 hours (p<0.05, denoted by 
*), as well as after 24 hours (p<0.0001, denoted by **). For microtissues treated with 
Blebbistatin, very statistically significant inhibition of compaction was observed after 24 hours 
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Chapter 5: Adaptation of the microtissues platform for long-term studies of ECM 
remodeling 
This chapter contains material from “A High-Throughput Workflow to Study 
Remodeling of ECM-Based Microtissues” by Alexandra L. Crampton*, Katherine A. 
Cummins*, and David K. Wood. Tissue Engineering Part C: Methods, volume 25, issue 
1, pages 25-36, 2019; permission conveyed through Mary Ann Liebert, Inc., New 




Changes to the cellular microenvironment are an integral characteristic of 
numerous pathologies including cancer, fibrosis, and autoimmune disease. Current in 
vitro methodologies available to study 3D tissue remodeling are ill-suited for high-
throughput studies as they are not scalable for large-scale experiments. Combining 
droplet microfluidics and patterned low-adhesion culture surfaces, we have engineered a 
workflow to incorporate cell-ECM interactions in a versatile and high-throughput 
platform that is compatible with existing high-throughput liquid handling systems, 
enables long-term experiments (>1 month), and is well-suited for traditional and novel 
biological measurements. With our platform, we demonstrate the feasibility of high-
throughput ECM remodeling studies with collagen microtissues as one application of a 
tissue-level function. In this study, we use our workflow to examine ECM remodeling at 
the tissue, cell, and subcellular levels, leveraging assays ranging from 
immunohistochemistry and live-cell imaging, to proliferation and contraction assays. 
With our unique culture system, we can track individual constructs over time and 
evaluate remodeling on several scales for large populations. Using these methods, our 
ECM-based system becomes a viable platform for modeling diseases characterized by 
tissue reorganization as well as a scalable method to conduct in vitro cell-based assays for 
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Impact Statement 
The described microtissue-microwell workflow is uniquely suited for high-
throughput study of ECM remodeling at the molecular, cellular, and tissue-levels and 
demonstrates possibilities of studying progressive, heterogeneous diseases in a way that 
is meaningful for drug discovery and development. We outline several assays that can be 
utilized in studying tissue-level diseases and functions that involve cell-ECM interactions 
and ECM remodeling (e.g. cancer, fibrosis, wound healing) in the pursuit of an improved 
3D cell culturing system.  
 
Introduction 
Alteration to extracellular matrix (ECM) composition and organization is a key 
hallmark of several diseases including cancer28–30, fibrosis28,31,32, and autoimmune 
disease31,33,34. The ECM not only provides structural support and enables cell-ECM 
signaling but acts as a reservoir for endogenous growth factors112–115, behaves as a barrier 
to therapy116–118, and participates in generation of bioactive protein fragments involved in 
diseased state cell signaling119,120. Furthermore, these pathologies progress and evolve 
over time, and tissue disorganization requires prolonged periods to fully develop. 
Mechanisms that involve cell-ECM interactions and remodeling over time are prominent 
in cancer, fibrosis, and autoimmune research and are favored targets for drug 
development however there remains an unmet need for model systems that could be used 
in the initial stages of drug development at a tissue level121,122. Further, ECM remodeling 
is difficult to visualize and quantify especially in the case of degenerative disease as these 
timescales can be difficult to recapitulate in vitro, revealing a need for platform that is 
compatible with high-throughput screening and retains complex cell-cell, cell-ECM, and 
architectural cues while enabling quantification of cell behavior over time. 
Current in vitro methodologies available to perform high-throughput and long-
term culture studies include both standard two-dimensional culture and spheroids12,123–125 
but they are ill-suited for probing the mechanisms of matrix remodeling as they lack an 
ECM component126,127. Platforms that are more appropriate for addressing these 
questions exist, however fabrication is rate limiting and handling is time consuming, 
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ultimately reducing sample size and preventing use for high-throughput applications. The 
most relevant examples are large hydrogels and microfluidic model systems. Hydrogels 
allow for incorporation of ECM proteins and are compatible with automated liquid 
handling systems, but they require substantial volumes of matrix and cells, elevating cost 
and reducing throughput with finite cell sources. Furthermore, these gels are often so 
large they are: 1) limited by diffusion, reducing nutrient transport and constraining 
staining choices57,128, and 2) restricted in compatible imaging modalities58–60. 
Microfluidic devices meanwhile provide opportunities to incorporate spatial organization, 
can integrate multiple matrix proteins, and require smaller reagent volumes than other 
methods129–131. However, these platforms depend on consistent tissue geometry to 
maintain complex flow patterns, development of chemical gradients, and the ability to 
track movement of cells over time, making compaction to physiologically relevant ECM 
densities difficult to study. In addition, chip scalability is limited even with advanced 
device design, indicating a persistent need for high-throughput ECM remodeling 
platforms. 
Leveraging droplet microfluidics, we have previously demonstrated use of 
protein-based microtissues for high-throughput, short-term studies of cellular phenotypes 
and interactions with ECM132,133.  To expand the capabilities of our microtissue platform, 
we engineered a workflow that couples microtissue fabrication with culture in patterned 
agarose microwells in a manner that is compatible with existing liquid handling 
techniques, enables long-term experiments (>1 month), and is well-suited for several 
traditional and novel biological measurements. Here we demonstrate compatibility of our 
long-term ECM-based culture platform with several molecular, cellular, and tissue level 
measurements to assess cell phenotype and function (Figure 5.1). In this study, we focus 
on ECM remodeling as a tissue level function that is quantifiable in our platform and is 
highly relevant to developing therapeutics for cancer, fibrosis, and autoimmune disease. 
We demonstrate that we can quantify local and global compaction, reversible and 
irreversible remodeling, and heterogeneity in compaction rates of individual microtissues. 
Using these methods, our ECM-based system becomes a viable platform for modeling 
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diseases characterized by tissue reorganization as well as a scalable method to conduct in 
vitro assays for drug screening and high-throughput biological discovery. 
 
Materials and Methods 
Cell culture 
Normal human lung fibroblasts (NHLF) were cultured in FGM-2 (Lonza) 
supplemented with 1x antibiotic-antimycotic and used between passage 3 and 7. National 
Institute of Health 3T3 (NIH 3T3) cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) with 10% fetal bovine serum (FBS) and 1x antibiotic-antimycotic and 
were used between passage 15 and 20. MDA-MB-231 cells were cultured in the same 
DMEM-based media and used at passage 9. Lastly, human umbilical vein endothelial 
cells (HUVEC) were cultured on gelatin coated flasks in EGM-2 (Lonza) and used at 
passage 2. Cells were released from flasks with 0.05% trypsin-EDTA and trypsin was 
neutralized with respective growth media before counting cells. 
  
Microtissue fabrication 
Collagen microtissues approximately 300 µm in diameter were fabricated using 
previously established protocols132,133. Briefly, high concentration rat tail collagen I 
(Corning) was buffered with 10x Dulbecco’s phosphate-buffered saline (DPBS), 
neutralized to pH 7.4, and diluted to a concentration of 6 mg/mL. For cell-laden 
microtissues, cells were resuspended in the collagen solution to a final concentration of 2 
million cells/mL. At 4°C, the collagen solution was partitioned into droplets using a flow-
focusing polydimethylsiloxane (PDMS) (Dow Corning) microfluidic device. The 
continuous phase from the droplet generation (FC-40 with 2% 008-FluoroSurfactant, Ran 
Biotechnologies), was collected with the collagen microtissues in a low retention 
Eppendorf tube and polymerized for 20 minutes at room temperature. The oil phase was 
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Polystyrene multi-well plates were coated with a thin layer of 2% agarose and 
dehydrated in a sterile laminar flow hood overnight. PDMS stamps featuring a radial 
pattern of 300 µm diameter posts were plasma treated for 2 minutes to produce a 
hydrophilic surface and sterilized with boiling water. For a 24-well plate, 175 µL of 
molten 2% agarose solution was pipetted into each well and the hydrophilic PDMS stamp 
placed immediately onto the agarose. After cooling for 5 minutes, stamps were removed 
gently from the polymerized agarose and hydrated with DPBS. Wells were washed with 
appropriate culturing media prior to adding microtissues with a manual micropipette. The 
stamped plates are referred to as “microwell plates.” 
 
Microtissue coating protocol 
50,000 cells were added to each well of a microwell plate and allowed to settle 
into the microwells for 5 minutes. Acellular microtissues were then added and allowed to 
settle into microwells. Finally, an additional 50,000 cells were added, sandwiching the 
tissues between two layers of cells. 
 
Viability assays 
Microtissues containing encapsulated cells were fabricated and cultured for up to 
1 month. At various timepoints, tissues were gently pipetted and removed from 
microwells and collected in an Eppendorf tube. For viability staining, constructs were 
washed thoroughly with DPBS and then incubated with a staining solution of 5 µM 
DRAQ5 (Invitrogen) and 5 µM Calcein AM at 37°C for 20 minutes. A Zeiss Axio 
Observer was used to image z-positions throughout each microtissue with a step size of 
10 µm, which is sufficiently small to account for each cell. Collected z-stacks were 
analyzed and the total number of cells (from the nuclear stain) and the number of live 
cells (from the Calcein) were counted for each microtissue. The percentage of live cells 
for each construct was calculated and reported values are for populations of microtissues 
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Following the protocol outlined in Chapter 4.2 Methods, projected areas and 
shape descriptors were measured by thresholding images of encapsulated fluorescent, 1 
µm diameter Fluoro-Max Microspheres (Thermo Scientific). Outliers, determined as 
areas three standard deviations above or below the average, were removed from the data 
sets. 
 
SHG imaging and analysis 
NHLF-coated microtissues were incubated in 0.1%, 2%, and 10% FBS and 
collected and fixed with 3.7% formalin after 1 and 3 days of culture. Nuclei were stained 
with 80 nM Hoechst before the constructs were immobilized in 1% agarose for imaging. 
Second harmonic generation (SHG) signal from the collagen fibers was collected with a 
custom multiphoton laser-scanning microscope (Prairie Technologies/Bruker) with a Mai 
Tai Ti:Sapphire laser (Spectra Physics). Fibers were excited at 880 nm. SHG signal 




Microtissues were cultured for up to 5 days, with collections at 2 hours and 1, 2, 
and 5 days. At each timepoint, half of the tissues were fixed with 3.7% formalin and the 
remaining microtissues were washed with DPBS and incubated in 5 mM EDTA solution 
at 37°C overnight before fixation with formalin.  
 
Immunofluorescence staining 
Microtissues were collected in low-retention Eppendorf tubes and fixed with 
3.7% formalin overnight at 4°C. Formalin was quenched with 0.1 M glycine and 
constructs were blocked and permeabilized with 10% FBS and 0.1% Triton X-100 for 1 
hour at room temperature. The tissues were then incubated with primary antibody (rabbit 
anti-fibronectin (1:200, Abcam), mouse anti-collagen IV (1:200, Abcam)) at 4°C 
overnight. The microtissues were washed thoroughly, and incubated with secondary 
antibodies (1:200, Jackson) and/or phalloidin (1:100, Santa Cruz Biotech) at 4°C 
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overnight. Nuclei were visualized with 20 µM Hoechst. A Zeiss Axio Observer with 
Apotome was used to obtain optical sections. 
 
Tracking and multiplexing 
Collagen microtissues containing 1 µm Fluoro-Max Microspheres and 
encapsulated NHLFs were cultured in 0.1%, 2%, and 10% FBS for a period of 6 days and 
imaged at several timepoints. Cultures were maintained with half-volume media changes 
every other day. On the final day of the experiment, tissues were fixed in microwells with 
3.7% formalin and then stained with phalloidin (1:100, Santa Cruz Biotech). Microtissues 
were then imaged on widefield in microwells using a Zeiss Axio Observer. A semi-
automated custom macro was used to calculate the projected tissue area for all timepoints 
and, for the final timepoint, actin fluorescence was also quantified. 
 
Statistical analysis 
 All experiments reported in this manuscript were completed at least 3 times with 
similar results. Statistical significance of EDTA release experiments was performed with 
paired t-tests and significance was determined using Bonferonni’s correction. 
Significance of tracking experiments was calculated with a student’s t-test. Lastly, 
ANOVA with Scheffé’s method where p-values less than 0.05 were considered 
significant was used to determine significance in SHG experiments. 
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Results 
The combination of droplet technology and agarose microwells enables a high-
throughput workflow and long-term culture of protein-based microtissues 
A major hurdle that must be overcome in any high-throughput tissue engineering 
application is scalability of construct fabrication as well as the cost and availability of 
required reagents. To address these concerns, our protocol leverages a microfluidic flow-
focusing device to produce tens of thousands of nanoliter-volume microtissues per hour 
(Figure 5.1). We fabricate more than 20,000 microtissues using the same reagent volume 
as is used to cast 6 traditional hydrogels in a 96-well plate. Additionally, all described 
experiments utilized a maximum of 20 cells per construct, meaning these assays could be 
scaled for large compound-screens with a limited number of cells.  
Although we have previously demonstrated that these protein-based microtissues 
are useful for observing short term tissue remodeling, it has been widely documented that 
most 3D tissue culture systems, including our microtissues, typically aggregate in static 
culture (Figure 5.2a), limiting their use for long term culture and high content 
readouts65,134,135. To address this challenge, we fabricated patterned agarose microwells 
using PDMS molds (Figure 5.2c,d). We chose agarose as it is affordable, but also 
biocompatible, amenable to patterning, does not bind to proteins or cells, and has 
precedence in the field for this purpose136–139. It also does not interact with compounds of 
diameters <60nm140,141, making this an ideal material for small molecule compound 
screening. These microwells physically separated microtissues and prevented aggregation 
(Figure 5.2e). When microtissues were cultured in commercially available low-adhesion 
plates, we observed a reduction in individual microtissues over a period of 1 week as they 
coalesced at the center of the well and formed aggregates (Figure 5.2a), resulting in a 
600-fold reduction in individual microtissues (Figure 5.2b). By contrast, microtissues 
cultured in microwells demonstrate no loss in the population over 1 week (Figure 5.2b). 
With the microwell culturing method, we cultured microtissues as independent entities 
for up to 1 month (greater than 90% viability of encapsulated NHLFs after 30 days). 
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Below, we demonstrate the utility of this platform and workflow for quantifying tissue 
remodeling. 
 
Long-term compaction of microtissues reveals reversible and irreversible ECM 
remodeling by fibroblasts and endothelial cells 
Wound healing is an ECM remodeling process involving fibroblast-driven wound 
contraction followed by ECM deposition and crosslinking to return mechanical integrity 
to a tissue. In vivo, this process occurs over the span of days to weeks, making it difficult 
to study with short-term in vitro model systems lacking an ECM component. Using our 
microtissue-microwell platform and leveraging its long-term culturing abilities, we 
modeled this dynamic wound-healing process with NHLFs in collagen constructs. For the 
purposes of this study, we used short-term culture to refer to timepoints that occur before 
48 hours of culture, a conservative estimate for protein synthesis to occur, and use the 
phrase long-term to denote culture greater than 2 days. To identify reversible and 
irreversible changes to ECM over short and long timescales, we collected tissues at 
various stages of remodeling and examined ECM compaction and deposition before and 
after cell release. There are several enzymatic methods to remove cells from ECM, but 
many of these treatments are detrimental to the structural integrity of the ECM itself. 
Thus, we elected to use EDTA as it destabilizes calcium- and magnesium-dependent 
integrin linkages, and is a gentle and minimally disruptive agent for both the cells and the 
matrix. From widefield imaging we found that the fibroblasts compacted the collagen 
microtissues (Figure 5.3a), but permanence of this remodeling was not immediately 
evident. Cell-ECM interactions likely stabilize microtissue compaction, and thus 
releasing cells would result in an increase in projected area for the tissue constructs. For 
both encapsulated and surface-coated NHLF conditions, we treated constructs with 
EDTA after 24 hours of culture and we found significant expansion of 33.3% and 24.5% 
respectively (p<0.00025). The reversibility of ECM compaction decreased over time, 
with the cell release resulting in no significant expansion for encapsulated and surface-
coated conditions (Figure 5.3b).  
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After observing irreversible matrix expansion after 5 days, we hypothesized that 
ECM deposition may contribute to remodeling as microtissue compaction did not 
increase greatly from days 1 and 2 to day 5. Using immunofluorescence, we found that 
after 5 days of culture cells deposit collagen IV and fibronectin when encapsulated in or 
coated on collagen I microtissues. Furthermore, in addition to removing the cells, EDTA 
disrupted collagen IV, a finding observed previously142,143. Incubating in EDTA solution, 
however, did not affect synthesized fibronectin and deposition of this and other matrix 
proteins not vulnerable to chelating agents may have prevented microtissue expansion 
(Figure 5.3c).  
In addition to fibroblasts, endothelial cells also participate in ECM remodeling, 
and to probe this endothelial function, we measured microtissue compaction of HUVEC 
coated microtissues. The endothelialized constructs were only minimally compacted after 
24 hours (Figure 5.3b) and thus did not show significant expansion after cell release, a 
distinct difference to the nearly total amount of compaction performed by NHLFs in the 
first 24 hours. After 2 days, however, we observed a significant expansion of 12.2% 
(p<0.012) with EDTA treatment (Figure 5.3b) as the HUVECs were able to contract and 
compact the matrix beneath them but again calculated no significant difference (2.6%) 
after 5 days of culture. This inability to detect reversible changes in construct size at late 
timepoints mimicked the behavior of both coated and encapsulated NHLFs. Although our 
results show that HUVECs compact microtissues more slowly than NHLFs, endothelial 
cells are also able to make irreversible changes to the ECM (Figure 5.3b). Staining of 
extracellular matrix proteins confirmed that matrix was deposited at later time points in 
endothelial cell conditions as well (Figure 5.3c). These results show that ECM 
remodeling by different cell types follow unique time courses, but it may also be possible 
that there is heterogeneity within the remodeling time course even within the same cell 
type. As microwells enable long-term culture and retention of individual microtissues in a 
consistent spatial arrangement, we can gather additional time scale related data through 
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Long-term tracking of individual microtissues reveals heterogeneity in cell-ECM 
interactions 
We have previously shown that ECM-based microtissues can be used for high-
throughput, short-term compaction assays132, and we here demonstrated how microwells 
can extend the experiment duration (Figure 5.2a). In addition, our ability to retain 
microtissues as discrete samples in the same spatial arrangement allows for identifying 
and tracking constructs as unique entities to enable characterization of subpopulations. 
Over 1 week, we tracked compaction for over 125 fibroblast-laden microtissues per 
condition (Figure 5.4a) and observed a distribution of compaction rates, with most major 
changes in size occurring on days 1, 2, and 4 (Figure 5.4b, c). Despite different 
compaction rates we observed that nearly all microtissues compacted to similar sizes 
(final area of 13,000 µm2), with the greatest difference in projected area observed on days 
1 and 2 (Figure 5.4d). Plotting the probability density function for each serum condition 
revealed a bimodal population on days 1 and 2 that returned to a unimodal distribution by 
day 4 (Figure 5.4e, f) indicating that a heterogeneous population of microtissues existed 
in each condition and that our system enables us to quantify these divergences within an 
experimental condition. Characterizing construct-level heterogeneity in our microtissue 
populations is beneficial as histology of pathologies like cancer and fibrosis are variable 
throughout the diseased tissue. 
To better understand the molecular origin of this heterogeneity, we visualized the 
cytoskeleton of cells within microtissues and found that tissues cultured in high serum 
expressed more actin than those cultured in low serum conditions (p<0.0001) (Figure 
5.4g). As expected, we found that microtissues in 10% serum were not only on average 
brighter but compacted faster, decreasing to 30% of their original projected area more 
quickly than microtissues in the 0.1% condition (p=0.002). Additionally, we also found 
variation in the actin intensity within each condition. As the staining protocol did not 
disturb microtissue positions, we compared the compaction profile and the actin signal on 
an individual microtissue basis. For each microtissue, we calculated the timepoint at 
which the projected area had decreased by 30% and compared this value to the final 
phalloidin intensity. We found microtissues that compacted faster demonstrated increased 
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actin intensity: we calculated a Pearson’s correlation coefficient of -0.68 and -0.65 for 
0.1% and 10% FBS conditions respectively between these variables, indicating a strong 
negative linear relationship for both conditions (Figure 5.4g). By combining the 
contraction assay with immunofluorescence, we observed that actin intensity was related 
to but not directly correlated with final microtissue size.  
 
Cells remodel microtissues on a local and global scale 
Increased density of collagen and other ECM components is proportional to the 
stiffness of a tissue, an important factor in cancer and fibrosis144–146. Multiphoton 
microscopy is a well-established tool used to investigate changes to global and local 
collagen densities through visualization of second harmonic generation (SHG) signal. 
Increased signal correlates to a higher density of fibers and it is known that cells will 
organize and bundle fibers both in vivo and in vitro45,147,148. Using SHG, we visualized 
changes in local collagen density and observed changes in both global and local ECM 
remodeling. First, we confirmed the fibrillar nature of acellular microtissues. We 
observed collagen fibers throughout the constructs and found they projected out of the 
microtissue free boundary surface, demonstrating their entangled nature and complex 
topography (Figure 5.5a). Then, to assess ECM remodeling via collagen fiber 
organization and bundling, we examined collagen microtissues coated with fibroblasts. 
As found in analogous large gel studies, we observed high serum conditions resulted in 
significant ECM remodeling149,150, with a statistically significant increase in SHG signal 
with 10% serum (Figure 5.5b). At early timepoints for all conditions, we observed 
increased collagen fiber intensity adjacent to nuclei, indicating that local remodeling and 
compaction of fibers is predictably occurring nearest to cells. After 3 days in culture, the 
global ECM remodeling was more evident as this localized intensity change was less 
apparent and the entire construct exhibited elevated SHG signal (Figure 5.5a). We also 
observed that higher serum concentrations resulted in more significant changes to overall 
construct shape, changing the circularity from 0.88 to 0.47 after 3 days of culture in 10% 
FBS (Figure 5.5c).These differences in collagen density may help explain the 
discrepancy in actin intensity staining observed in NHLFs cultured in low (0.1%) and 
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high (10%) serum culturing conditions (Figure 5.4g) despite similar construct size as was 
quantified from widefield imaging.  
 
Discussion 
In the context of high-throughput screening, maintaining large populations of 
discrete microtissues is critical for feasibly completing large-scale experiments, and our 
agarose microwells enable such a workflow. When used in conjunction with agarose 
microwells, we cultured upwards of 500 microtissues per well in a standard 24-well plate, 
which equates to large numbers of conditions and hundreds of replicates per condition in 
any given experiment. Additionally, the familiar well-plate format of our microtissue-
microwell platform is compatible with automated liquid handling techniques and 
automated imaging systems, making this culture method a practical system for large-scale 
screening. We conducted our studies in 24-well plates as a proof-of-concept to show the 
potential of this platform for use in larger-scale studies. However, this microwell system 
could be adapted to 96- or 384-well plates as the agarose patterning method is 
independent of well size. 
In this study, the application of this platform, allowed us to track individual 
constructs over time, measuring dynamic changes in overall construct geometry as well 
as performing endpoint readouts with a consistent spatial arrangement. Coupling 
compaction with other non-destructive live cell measurements (e.g. reporter lines or cell 
migration), we envision that tracking microtissues over time could provide time-lapse 
information on the development and progression of disease states in vitro. This would 
allow for testing the efficacy of therapeutics at several stages of disease as well as the 
long-term effects of drugs on specific populations. This could be particularly important 
for identifying drug-resistant populations in diseases such as cancer. If used in 
conjunction with primary cells from patient biopsies, these methods offer additional 
metrics to investigate drug efficacy on diseased cells’ ability to remodel and interact with 
their microenvironment. 
By tracking individual microtissues over time, we were able to observe that ECM 
remodeling by different cell types follow unique time courses and that there is 
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heterogeneity within the remodeling time course even within the same cell type. One 
likely driver of heterogeneity in the microtissue compaction rates is the variance in the 
initial cell seeding density. In large collagen hydrogels, the rate of collagen compaction is 
dependent on initial cell density, and in droplet systems, it is well characterized that cell 
encapsulation methods follow a Poisson distribution151. Notably, the microtissues 
eventually converge to a narrower distribution, which is consistent with previous 
literature suggesting that as gels approach a common smaller size, cell density reaches a 
critical threshold and becomes a less significant factor95. The workflow described here 
facilitates the simultaneous study of large numbers of replicate microtissues and thus 
enables the possibility to study heterogeneity that may derive from factors like cell 
number, variability in underlying ECM, and heterogeneity in the underlying cell 
population. 
We also found that compaction in our system was reversible at early timepoints, 
and over time the remodeling became more permanent. We examined the effects of 
encapsulating versus coating cells on the surface and found the surface-coated version to 
produce irreversible remodeling more quickly. Differences in cell numbers between these 
two conditions may also explain this observed effect. Because we encapsulated relatively 
low numbers of cells (<20 per microtissue), we may have had more cells adhered to the 
surface of the microtissues than were encapsulated. An alternative hypothesis is that the 
surface-coated NHLFs create a more stable ECM modification because the deposited 
ECM is supporting the remodeled geometry consistently from the outer edge of the 
microtissue. In comparison, the encapsulated fibroblasts deposit matrix throughout the 
microtissues, which provides less organized modification near the surface of the 
microtissues on average, as alluded to by the ECM staining results in Figure 5.3. Thus the 
surface deposition would provide more resistance to tissue expansion and thus would 
result in a diminished increase in size after releasing cells with EDTA.  
In combination with measuring tissue compaction as a functional assay, we have 
demonstrated the ability to measure molecular readouts that provide insight into the 
mechanistic drivers of the function. Notably, our microtissue platform permits 
simultaneous measurement and correlation of cell function (compaction) and molecular 
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mechanism (actin) in the same cells and in the same microenvironment. Previously, 
correlation of actin polymerization and its effect on gel contraction have been reported by 
separately measuring actin in a 2D culture  system while separately measuring 
compaction in a 3D bulk gel152,153. This separation of experimental readouts was required 
because the large size of the hydrogels hindered imaging58–60. Thus the scale of our 
system enables a more direct connection between mechanism and function. 
As our assays and protocols are modular and can be combined and used to assess 
tissue-level behaviors for a variety of applications, this platform becomes flexible and 
amenable to study wide classes of diseases.  
 
Conclusion 
 We have developed an in vitro platform that enables long-term tissue remodeling 
on a cellular scale for large populations. Using agarose microwells to culture collagen 
microtissues, we have cultured microtissues as independent entities for up to 1 month and 
have tracked and measured them as discrete tissues for 1 week. Additionally, we have 
quantified both local and global as well as short and long-term remodeling that occurs in 
our culturing system. Establishing high-throughput metrics of remodeling is crucial for 
development of drug screening models for fibrotic and cancerous disease, though the 
merit of the platform extends beyond these pathologies to include any disease in which 
ECM interactions are considered important. 
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Figure 5.1: The microtissue-microwell workflow facilitates functional and mechanistic 
analysis at multiple scales 
Our workflow facilitates studies of tissue remodeling and disease progression on tissue, cellular, 
and subcellular scales in short- and long-term studies, while visualizing global and local 
behaviors. This system is compatible with a wide range of cell types, ECM proteins, and 
biological assays, making this a practical solution for high-throughput fabrication and handling of 













Figure 5.2: Microwells enabled long-term culture of large microtissue populations  
(A) Brightfield imaging reveals that microtissues aggregate when cultured for 4 days in standard 
low adhesion plates. (B) Quantification of individual microtissues after 1 week of culture in 
standard low adhesion plates (blue bars) reveals that the population is reduced by over 100-fold. 
By contrast, microtissues cultured in patterned agarose microwells (red bars), remained separated 
over the same 1-week period. (C) To fabricate microwells, plasma-treated PDMS stamps with 
300-µm diameter posts were placed into 2% agarose solution and (D) removed once polymerized. 
(E) Brightfield combined with blue fluorescence imaging shows microtissues contained in 
agarose microwells in a 12-well plate. Microtissues are labeled blue by encapsulating blue 
fluorescent beads within the polymerized collagen matrix. Scale bars 500 µm. 
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Figure 5.3: EDTA release allows for studying microtissue remodeling on short and long 
timescales 
(A) Brightfield imaging of microtissues after 1 and 5 days of culture with encapsulated NHLFs or 
coated with NHLFs or HUVECs. The actin cytoskeleton was visualized with phalloidin (green) 
and nuclei with Draq5 (magenta). After 1 day, we observed a reduction in construct size, which 
was partially reversed after releasing cells with EDTA. After 5 days, this reversal was not 
observed. To quantify these effects with construct size, we measured (B) microtissue projected 
area and confirmed that on a population-scale at early timepoints, compaction was partially 
reversible, while after 5 days of culture remodeling was not reversible. We calculated 
significance with a paired t-test with a Bonferroni correction for multiple comparisons 
(p<0.00025 = ***, p<0.013 = *, standard error shown). Projected area is normalized to the 
average area of each microtissue batch after fabrication. (C) Fluorescence imaging with optical 
sectioning shows that fibronectin (green) and collagen IV (magenta) were deposited on the 
surface of the microtissues, however the collagen IV was disrupted by EDTA treatment. All scale 
bars 100 µm and sample sizes were an average of 38 microtissues per condition. 
 
	




Figure 5.4: Microwells facilitate tracking of discrete microtissues and coupling live imaging 
data with endpoint staining  
(A) Brightfield and fluorescence imaging of collagen microtissues containing NHLFs and 
encapsulated fluorescent beads (blue) to mark construct borders were cultured in 0.1% (or 10%) 
serum for 1 week. All scale bars 100 µm. (B, C) Areas of 121 individual microtissues cultured in 
0.1% FBS (B) and 137 constructs cultured in 10% FBS (C) were measured and plotted. A red 
dashed line indicates a threshold compaction level of 30% compaction. Projected area is 
normalized to day 0 for each microtissue compaction trajectory. (D) Population averages show 
similar compaction trajectories between 0.1% and 10% serum conditions. Shown with standard 
error. (E, F) Probability density functions of microtissue area at each timepoint reveal 
heterogeneity in the populations, indicated by bimodal distributions on day 1 (red) and day 2 
(yellow) populations. (G) We observed a strong negative correlation between actin intensity and 
the time at which a 30% reduction in projected area occurred, as indicated by correlation 
coefficients of -0.68 (orange linear trendline) and -0.65 (red linear trendline) for 0.1% and 10% 
FBS conditions respectively. This suggests that a faster compaction rate is correlated to increased 
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actin expression. We also found that higher serum conditions corresponded to elevated actin 
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Figure 5.5: SHG microscopy revealed local ECM remodeling of collagen constructs  
(A) Acellular collagen microtissues were coated with NHLFs and cultured for 3 days in varying 
serum concentrations. Collagen compaction and ECM remodeling were observed using SHG to 
visualize collagen fibers (grey) and Hoechst to stain the nuclei (blue). A section of an acellular 
slice is magnified (scale bar 50 µm) and the brightness adjusted to demonstrate the complex 
topography and fibrilar nature of the constructs. (B) Increased SHG signal intensity correlates to 
increased collagen fiber density and we qualitatively observed that with increasing serum and 
incubation time, cells interact with and increasingly modify their microenvironment. All other 
scales bars are 100 µm. (C) Average signal intensity from the collagen fibers was determined for 
each optical slice for each condition (n=4-6 microtissues per condition). We observed that as 
serum concentrations increase, collagen fiber density increases due to compaction of fibroblasts. 
(D) Circularity of each construct is reported and with increasing serum concentrations and time, 





 57  
Chapter 6: Application – Endothelial micromimics for high-throughput drug screening 
This chapter contains material from “A High-Throughput Microtissue Platform to 
Probe Endothelial Function In Vitro” by Alexandra L. Crampton, Katherine A. Cummins, 
and David K. Wood. Integrative Biology, volume 10, issue 9, pages 555-565; permission 
conveyed through Copyright Clearance Center, Inc. 
 
Overview 
A critical role of vascular endothelium is as a semi-permeable barrier, 
dynamically regulating the flux of solutes between blood and the surrounding tissue. 
Existing platforms that quantify endothelial function in vitro are either significantly 
throughput limited or overlook physiologically relevant extracellular matrix (ECM) 
interactions and thus do not recapitulate in vivo function. Leveraging droplet 
microfluidics, we developed a scalable platform to measure endothelial function in 
nanoliter-volume, ECM-based microtissues. In this study, we describe our high-
throughput method for fabricating endothelial-coated collagen microtissues that 
incorporate physiologically relevant cell-ECM interactions. We showed that the 
endothelial cells had characteristic morphology, expressed tight junction proteins, and 
remodeled the ECM via compaction and deposition of basement membrane. We also 
measured macromolecular permeability using two optical modalities, and found the cell 
layers: (1) had permeability values comparable to in vivo measurements and (2) were 
responsive to physiologically-relevant modulators of endothelial permeability (TNF-α 
and TGF-β).  This is the first demonstration, to the authors’ knowledge, of high-
throughput assessment (n>150) of endothelial permeability on natural ECM.  
Additionally, this technology is compatible with standard cell culture equipment (e.g. 
multi-well plates) and could be scaled up further to be integrated with automated liquid 
handling systems and automated imaging platforms. Overall, this platform recapitulates 
the functions of traditional transwell inserts, but extends application to high-throughput 
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Introduction 
The vascular system serves crucial roles in supplying nutrients to and removing 
wastes from peripheral tissues, facilitating immune cell trafficking, and maintaining 
osmotic homeostasis. These functions depend on the endothelium to act as a semi-
permeable barrier between the blood and tissue, which requires the body to regulate and 
modulate endothelial permeability and thus the flux of cells and/or solutes across the 
barrier. For example, in inflammatory processes, the endothelial barrier becomes more 
permeable, facilitating transport of immune cells into the tissue space and inflammatory 
signals out in order to support the immune response.154,155 Endothelial barrier function 
may also be disrupted in disease processes (e.g. atherosclerosis156–158, rheumatoid 
arthritis159–161), leading to local changes in transport of proteins, fluid volume, and cell 
populations (including immune cells) into the surrounding tissue. There is also a growing 
recognition that endothelial barrier function is a critical consideration for delivery of 
many classes of therapeutics, which can be hindered (e.g. blood-brain barrier162–166) or 
enhanced (e.g. enhanced permeability and retention in solid tumors167–172) due to 
endothelial regulation. Our ability to understand how endothelial barrier function is 
(dys)regulated in health and disease and how it affects delivery of therapeutics requires 
robust models of the endothelium and accurate measurement of the barrier function. 
One of the standard measurements of endothelial function in vitro is 
macromolecular permeability of monolayers grown on porous transwell 
inserts.162,166,173,174 Monolayers are cultured on the insert, and movement of various 
solutes across the cell layer are typically measured with colorimetric or fluorescently 
labeled solutes. Although cells attach and consistently form monolayers on these inserts, 
the endothelial layers are often more leaky than in vivo vessels.173,175–178.  One 
explanation for the discrpency between in vitro and in vivo measurements is that the 
interaction of the endothelium with the tissue compartment is also important for 
endothelial function. Others probed this hypothesis by coating transwell inserts with 
ECM molecules179,180, and found that the exclusion of maromolecular molecules was 
closer, but still not equivalent to in vivo measurements. These findings support the need 
to create in vitro platforms that recapitulate the endothelium in the context of an ECM-
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rich tissue space. Thus, there has been significant effort towards developing more 
physiologically relevant tissue-level models of vasculature in vitro using microfluidic 
devices.181–184 These models create complex vasculature that directly interacts with ECM 
and demonstrates characteristic morphology and barrier function.  However, the low 
throughput of these platforms ultimately limits utility for high-throughput screening, 
revealing a need for an in vitro model of the endothelium that is robust, recapitulates the 
endothelium-ECM interactions in a physiologically meaningful way, and is also 
amenable to high-throughput studies. Our group132 and others80,185,186 have shown that 
microcarrier systems can be used to culture endothelial cells, however dynamic 
measurements of endothelial behavior (e.g. ECM deoposition, changes in endothelial 
permeability) have yet to be characterized in a high-throughput manner.   
Combining the rich cell-ECM interactions of microfluidic platforms and the high-
throughput capabilities of droplet technology, we used ECM-based droplets as a substrate 
for endothelial cells to grow and remodel (via compaction and ECM deposition) – 
capturing the endothelium-ECM interactions in a format that is compatible with rapid 
fabricaiton.   We demonstrate that microscale (~300 µm diameter) collagen microtissues 
can be used as ECM-rich carriers on which to culture endothelial cells and can be used to 
assess factors that regulate endothelial barrier function. These microtissues are fabricated 
using flow-focusing microfluidic devices, generating ~20,000 droplets/hour, making this 
ECM-based platform amenable to large-scale studies of endothelial permeability. We 
show that characteristic behaviors of in vitro endothelial layers (confluence of the 
monolayer, deposition of ECM, and behavior of the semi-permeable barrier) are observed 
in our microtissue constructs.  Additionally, we show for the first time to the authors’ 
knowledge, high-throughput assessment of endothelial function on natural ECM, 
supporting robust statistical analysis and feasability for large-scale applications.  
Miniaturization of tissues also minimizes cell number requirements, making this platform 
amenable to precious cell and ECM sources.  We also demonstrate that we can detect 
biologically relevant modulators of endothelial permeability, using inflammatory 
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Methods 
Microtissue fabrication 
Acellular collagen microtissues were fabricated with a modified protocol outlined 
previously (Figure 6.1).132  Briefly, High Concentration Rat Tail Collagen I (Corning) is 
buffered with 10x PBS, pH adjusted to 7.4, and diluted to a final concentration of 6 
mg/mL.  At 4°C, the collagen solution was partitioned into microtissues using a flow-
focusing microfluidic device.  The continuous phase from the droplet generation (FC-40 
with 2% EA Surfactant, Ran Biotechnologies), was collected with the collagen 
microtissues in an eppendorf tube.  Microtissues were polymerized in bulk at room 
temperature for 20 minutes.  The oil phase was drained and microtissues were 
resuspended in 1X sterile PBS. 
 
Microtissue endothelial coating 
Human Umbilical Vein Endothelial Cells (HUVECs) were cultured in EGM-2 
(Lonza) on gelatin-coated flasks.  Cells were used between passage 2 and 4 for all 
experiments.   Cells were washed with HBSS and released from the culture flask using 
0.05% trypsin (Gibco).  Trypsin was neutralized with media, washed with fresh media, 
and counted.  In 12-well low adhesion plates (coated with agarose), 350-500k cells were 
added to ~750 collagen microtissues.  Constructs were cultured in these low-adhesion 
plates for 5 days, with media changes every 2-3 days.  Coated microtissues were 
recovered from plates with gentle pipetting for experiments.  
 
Crosslinking collagen microtissues 
Stiffness of collagen microtissues was increased by crosslinking with formalin. 
Microtissues were incubated with 3.7% formalin for 1 hour at room temperature.  Tissues 
were washed thoroughly with 1X PBS to dilute formalin to <0.001%.   
 
Immunofluorescence staining 
Coated constructs were collected and fixed with 3.7% formalin for at least 1 hour 
at room temperature.  Microtissues were washed with 1X PBS, then quenched with 25 
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mM glycine. Microtissues were washed, then blocked and permeabilized with 1% BSA 
and 0.1% Triton X-100.  Primary antibodies (VE-Cadherin (Cell Signaling), CD31 (Cell 
Signaling), Laminin (Abcam), Collagen IV (Abcam)) were diluted in 1% BSA to ratios 
of 1:100-1:500.  Secondary antibodies (Jackson) were diluted in 1% BSA to a ratio of 
1:500.  Each sample was incubated with 100 uL of antibody solution for either 2 hours at 
37°C or overnight at 4°C.   Nuclei were labeled with Hoechst (Invitrogen) or Draq5 
(Invitrogen).   
 
Permeability measurement 
After culturing microtissues for 5 days, microtissues were collected and placed in 
a large volume of 12.5 µg/mL 150 kDa TRITC-dextran (Sigma) in a 96-well plate coated 
with pHEMA (Sigma).  Dye diffused into the droplets for 20 minutes before imaging at 
10X with the Zeiss Axio Observer.  To obtain optical sections, an Apotome was added to 
the light path and 5 images per slice were collected.  Images from both methods were 
analyzed for local intensity using custom macros written in Fiji.187 Modulators of 
permeability were 5 mM EDTA, 10 ng/mL TNF-α (Sigma), 2 ng/mL TGF-β (Sigma). 
To calculate permeability from optical sectioning, we assumed the microtissues 
initially had no fluorescent solute inside the tissue and that all of the solute must pass 
through the endothelial barrier to reach the center of the tissue.  We established an 
unsteady mass balance where the number of moles of solute on the inside of the tissue 
was equivalent to the moles of solute that had crossed the endothelial barrier.  This was 
described as:   
!!!"#$
!"
𝑉!"#$ = 𝐴!𝑃 𝐶!"#! − 𝐶!"#$     (1)  
where Cdrop was the molar concentration of solute inside the microtissue, Vdrop was the 
volume of the microtissue, Am was the surface area of the microtissue, P was 
permeability, and Cbath was the concentration of the dye bath.  As Vbath was much greater 





𝑃 𝐶! − 𝐶!"#$      (2). 
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We solved for Cdrop and applied the initial condition that Cdrop = 0 when t=0. This resulted 
in the final expression for permeability as: 






    (3). 
 Additionally, by removing the cell layer using EDTA and calculating permeability of the 
remodeled ECM, we can identify the contribution of the cell layer and the construct itself 







     (4). 
 
Second harmonic imaging to visualize collagen fibers 
Second harmonic imaging microscopy was used to visualize collagen fibers in 
microtissues.  Constructs were collected and mounted onto coverslips with 1% agarose.  
Agarose was chilled to polymerize the gel and the samples were kept hydrated with 1X 
PBS.  Constructs were imaged using a custom multiphoton laser-scanning microscope 
(Prairie Technologies/Bruker) with a Mai Tai Ti:Sapphire laser (Spectra Physics) exciting 




Large sample sizes allowed for parametric statistical analysis.  Comparisons for 
multiple groups were completed with one-way ANOVA with post-hoc Tukey HSD 
comparison.188 Results were reported as statistically significant with p-values less than 
0.05. 
 
Results and Discussion 
Endothelial cells form confluent monolayers and compact ECM microtissues 
It has been previously shown that endothelial cells compact ECM hydrogels in 
vitro106,189, and we expected that endothelial cells would also compact our collagen 
microtissues (Figure 6.1a,b). We further hypothesized that this tissue compaction would 
result in improved endothelial barrier function. Thus, to compare compacted and 
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uncompacted tissues, we created two types of collagen microtissues. “Soft” microtissues 
were generated with no post-polymerization modification as described in the Methods. 
“Stiff” microtissues were generated by crosslinking the polymerized collagen with 
formalin for 1 hour at room temperature, followed by extensive washing to remove  
residual fixative. Soft and stiff microtissues were then coated with endothelial cells as 
described in the Methods.  
As shown in Figure 6.2, endothelial cells formed confluent monolayers on the 
surface of soft and stiff collagen microtissues.  Microtissues were coated with endothelial 
cells and cultured for up to 5 days, and immunofluorescence was used to assess location 
and expression of VE-cadherin and CD-31.  We used optical sectioning to confirm that 
cells were on the surface of the microtissues and had characteristic cobblestone 
morphology (Figure 6.2a).  CD31 and VE-cadherin were detected at the intercellular 
interfaces of the cells as early as 24 hours after coating (data not shown) as well as 5 days 
after seeding (Figure 6.2a).  We also measured compaction by the endothelial cells using 
the projected area of collagen microtissues before and after coating with endothelial cells. 
We found that the average radius of soft microtissues decreased from 214.68 ± 15.21 µm 
to 118.66 ±10.32 µm (p<0.001) (Figure 6.2c).  As predicted, the average radius of stiff 
microtisues did not change significantly after coating with cells, with the average radius 
shifting from 225.28 ± 57.45 µm to 216.45 ± 25.39 µm  after 5 days of culture with 
endothelial cells (Figure 6.2d). Thus, we confirmed that our platform generates confluent 
monolayers of endothelial cells that interact with the collagen substrates via adhesion and 
tissue compaction – both of which are physiolgoically relevant endothelial functions.  
 
Endothelial cells anisotropically remodel collagen microtissues 
 To examine remodeling via compaction in more detail, we used second harmonic 
generation (SHG) to visualize the collagen architecture throughout the culture process 
(Figure 6.3a). We confirmed our finding that soft microtissues were compacted 
significantly more than stiff microtissues, and that the majority of this compaction was 
completed within the first 24 hours of culture.  We qualitatively observed that the image 
intensity is brighter for the compacted soft tissues than for the other conditions and 
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quantified this by measuring the average intensity for the entire construct (Figure 6.3b). 
The average intensity of the microtissues before and after crosslinking (on day 0) were 
not statistically different, indicating that the crosslinking process did not affect local 
collagen distribution or signal from this measurement.  We also found that the addition of 
cells to the stiff microtissues did not change their intensity across any of the days 
measured (one-way ANOVA, with post-hoc Tukey HSD test).  Contrastingly, soft 
microtissues showed a statistically significant increase in intensity in the first 24 hours 
after coating (p<0.01), and this difference was maintained in all subsequent timepoints 
(Figure 6.3b).  
  Although we observed a dense ring of bright collagen fibers immediately beneath 
the cell surface (Figure 6.3a), we wondered if our measured increase in SHG signal 
intensity was due solely to this dense ring under the cells or if the interior of the 
microtissue was also affected.  To quantify this, we took several linescans from the center 
to the edge of the microtissue.  We defined a significant increase in intensity to be at least 
5 times brighter than the initial measured intensity of acellular constructs (d0).  With this, 
we found that there was little to no remodeling of stiff microtissues in any region of the 
microtissue.  Conversely, the soft microtissues showed significant remodeling deep in the 
interior of the microtissues, with significant changes in intensity occurring up to 97 µm 
into the microtissue (Figure 6.3c).   
We found that endothelial cells not only change the diameter of soft microtissues, 
but also make fundamental changes to the structure of the ECM in the interior of the 
construct.   This predictable pattern of collagen remodeling makes this a simple method 
for creating dense collagen layers beneath the endothelial layer, which has previously 
required explicit patterning of ECM190. For the stiff constructs, we confirmed that 
endothelial cells adhere to and interact with the matrix, but were unable to compact the 
matrix on the local or global scale. 
 
Endothelial cells deposit basement membrane on collagen microtissues 
 Endothelial cells are known to not only compact ECM hydrogels, but also to 
deposit basement membrane proteins including collagen IV191–193, laminin193, and 
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fibronectin194 on in vitro substrates.  To assess this functionality in our platform, we 
cultured endothelial cells on both soft and stiff microtissues for 5 days.  We probed for 
basement membrane proteins using immunofluorescence and found that endothelial cells 
deposit collagen IV and laminin on the surface of both soft and stiff microtissues (Figure 
6.2b). This deposition of basement membrane to the surface of the microtissues 
transforms the plain, isotropic collagen I microtissues into a more physiologically-
relevant model of endothelium in vitro.  
The regulation of basement membrane layers is important in the dynamics of the 
endothelium.  For example, angiogenic processes require degradation of basement 
membrane before cells can migrate towards an angiogenic signal.195,196 Thus, the 
presence of basement membrane in our model system not only supports the existing 
endothelial layers, but also provides potential for a high-throughput model to study 
basement membrane dynamics in vitro.  
 
Endothelialized microtissues demonstrate permeability similar to that observed in vivo 
 One of the most important functions of the endothelium is to act as a semi-
permeable barrier, dynamically regulating the flux of solutes between blood and the 
surrounding tissue. The endothelium is selectively permeable, with transport of molecules 
larger thatn 40-70 kDa excldued very well by healthy endothleium183,197–199.  We opted to 
use a tracer comfortably larger than this range (150 kDa) to ensure exclusion by heathy 
endothelium and to afford more temporal flexibility for our imaging readouts. To assess 
macromolecular permeability, we examined the flux of 150 kDa TRITC-dextran through 
soft and stiff microtissues (Figure 6.4a).  To quantify the permeability, we first measured 
the fluorescence intensity inside and outside of the microtissues. We observed some 
variability in the absolute intensity of the bath (likely due to photobleaching200,201), but 
we found the difference in intensity between the interior of the microtissue and the 
surrounding dye bath to be more robust (we report this value as ΔI) (Figure 6.4b).  Using 
ΔI, we determined that the soft and stiff acellular constructs exhibit similar low 
impedance to the movement of dye, indicating that the initial stiffness of the construct 
alone does not affect dye transport for this assay.  Both endothelial coated conditions 
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showed a statistically significant increase in ΔI, with the soft-coated condition showing 
the largest increase in ΔI (Figure 6.4c).  Whether this difference was due to the cell layer, 
to ECM remodeling, or to both required us to examine the endothelium and the ECM 
separately.  To accomplish this, we removed the cell layer using EDTA, releasing the 
cells off of the surface of the microtissues and leaving the modified construct behind.  We 
found that the EDTA-treated samples had an intermediate phenotype between the 
acellular and cellular controls, indicating that the change in ΔI in these microtissues was 
due to both the impedance from the cell layer and from the remodeling of the constructs.  
To determine the contribution of each of these factors, as well as to compare our platform 
to other macromolecular flux assays, we used the calculated ΔI measurements to 
determine permeability.  
Using an unsteady mass balance, we found the average permeability of the 
acellular constructs to be 1.09 x10-07 ± 5.19 x10-08 cm/s and 1.26x10-07± 9.26 x10-08 cm/s 
for the soft and stiff microtissues respectively.  When a layer of cells is added to these 
constructs, there is a statistically significant decrease in average permeability to 5.29x10-
09 ± 1.6 x10-09 cm/s and 2.9710-08 ± 5.59 x10-09 cm/s for the soft and stiff constructs 
respectively.   Once the cell layer is removed using EDTA, we found that the average 
permeability was 6.56x10-09 ± 7.62 x10-10 cm/s and 4.98x10-08 ± 2.84 x10-08 cm/s for the 
soft and stiff constructs respectively (Figure 6.4d). For the stiff constructs, this EDTA 
treatment resulted in a statistically significant increase in permeability, but this effect was 
not observed for the soft constructs. Using these permeability values to calculate the 
cellular component with Eq. 4, we found the average permeability of just the cell layer to 
be 2.75x10-08 ± 1.30x10-08 cm/s and 7.34x10-08 ± 4.19x10-08 cm/s for the soft and stiff 
constructs respectively. Although the total construct permeabilities were very different 
between the soft and stiff conditions, the contribution of the cell layer alone was on the 
same order of magnitude.   
The measured permeability of our endothelial layers is lower than other reported 
values for endothelial cells with comparable tracers cultured in vitro173,198 and is 
comparable to permeabilities reported for vasculature in vivo202,203. It is well known that 
ECM interactions improve barrier function in vitro189,191,193,194, and thus we believe the 
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presence of these cell-ECM interactions explain the low permeabilities observed in our 
constructs.  Our endothelial layers (for both the soft and stiff conditions) demonstrated 
lower permeability values than reported for traditional systems, suggesting that even 
without the additional resistance to dye movement from compacted tissue, the cell-ECM 
interactions supported a more in vivo-like phenotype. Our soft and stiff constructs 
demonstrate different transport profiles, which is expected as increasing collagen 
concentration is known to increase resistance to macromolecular movement within the 
gels.  And thus, our platform is capable of represnting tissue-scale model to study 
endothelium (soft constructs) as well as an ECM-rich method to examine the endothelium 
on its own (stiff constructs).  This gives us the ability to mimic the in vivo environment of 
endothelium interacting with tissue, but also to observe changes to the endothelium in 
isolation.  Finally, our endothelial constructs demonstrate this lower permeability value in 
a short culture period of just five days whereas other groups require up to 15 days of 
culture to obtain comparable results175. Our expedient and versatile platform for 
measuring permeability makes our culture method more amenable to applications in 
biological discovery and drug screening.  
 
A high-throughput assessment of endothelial permeability with widefield imaging 
 Quantification of endothelial permeability using optical sectioning affords direct 
comparison with in vivo measurements, but collecting optical sections is significanlty 
more time-consuming than other modalities, which limits the throughput of the analysis.  
We hypothesized that by using the ΔI value from widefield images, we could semi-
quantitatively assess the permeability of endothelial-coated constructs, which would be 
appropriate for high-throughput studies in which comparison between conditions is more 
relevant than absolute quantification.  
 These experiments were conducted similarly to those described for the results in 
Figure 6.4. We first implemented a detection scheme that would accommodate a larger 
population of microtissues (Figure 6.5a).  With the brightfield channel, we used Fiji187 to 
threshold the images and bring microtissue constructs to the foreground.  We then 
converted these images to black and white, and used built-in object analysis tools to 
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detect the area, centroid, and edges of each construct.  Using the red fluorescence 
channels, we recorded the intensity across a line from the centroid of the microtissue to 
100 pixels outside the edge of the microtissue.  We repeated this intensity measurement 
for a total of 5 linescans per microtissue and averaged the results. This process was 
automated to expedite the image processing, with a runtime of 1.66 – 7.22 seconds per 
droplet analyzed. An example of an intensity profile for an endothelial-coated construct is 
shown (Figure 6.5a). With widefield imaging, we hypothesized that the majority of the 
out-of-plane signal would come from the dye bath above the microtissues.  To minimize 
noise from out-of-plane signal, we also introduced a larger size construct to our 
experiments, testing the original size (~200 µm radius) and a larger construct (~300 µm 
radius).  We qualitatively observed that the acellular microtissues appeared to be 
saturated with dye, whereas there was some exclusion of dye with the cell layers for both 
the endothelial-coated and EDTA-treated conditions (Figure 6.5b). We calculated the 
radius of the microtissues (Figure 6.5c), the average intensity inside and outside of the 
droplet, and used these values to calculate ΔI for widefield (Figure 6.5d). The images for 
each treatment group were collected in 55 seconds, and the average population size 
examined in this representative dataset is 152 microtissues.  
As with our previous experiments, we observed significant changes in the 
diameters of soft constructs (acellular vs. coated for all conditions p<0.01), and observed 
little to no effect when coating stiff microtissues with endothelial cells  (Figure 6.5c). 
Next, we examined the transport of 150 kDa TRITC-dextran across the endothelial layer 
(Figure 6.5d), which was expected to largely be excluded by a healthy endothelial barrier.  
For all size and stiffness combinations, we were able to detect a statistically significant 
change in ΔI between the acellular and coated conditions.  This again demonstrates that 
for all stiffness and size conditions, the addition of the endothelial cell layer created a 
barrier to solute transport -- either via the cell layer, changes to the ECM, or a 
combination of the two. Finally, we determined changes in ΔI could be detected with 
widefield imaging after perturbation of the cell layer by releasing cells with EDTA.  We 
found that with the small, soft condition, we were unable to detect a statistically 
significant change in ΔI; however, for the large and small stiff constructs as well as the 
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large, soft microtissues, the difference between the coated and EDTA treated conditions 
were statistically significant (p<0.01).  
Additionally, endothelial permeability is known to be modulated by 
cytokines180,204,205, hormones206,207, and endotoxins180,208. We tested the effect of two 
inflammatory cytokines – TNF-α and TGF-β  – which were expected to increase the flux 
of dye through the endothelial barrier by disrupting adherens junctions.  We found that 
for both sizes of stiff constructs, there was a statistically significant decrease in ΔI 
(comparing coated to either TNF-α treated or TGF-β treated, p<0.01), meaning that our 
assay detected the response to the inflammatory cytokines.  This change was not 
observed for either size of the soft constructs, likely due to the additional resistance to 
diffusion by the compacted ECM.  We have shown that using just widefield imaging, we 
can detect changes in permeability in response to inflammatory signals, using TNF-α and 
TGF-β for this sample case.   
There are several modes of endothelial disruption that are valuable to study in 
vitro.  We have shown that the effects of high-concentration chelating agents (e.g. 
EDTA) can be observed both with optical sectioning and with widefield measurements. 
This resulted in total physical disruption of the endothelial layer, which could represent a 
physical injury to the endothelium or could be used to study endothelial healing and 
remodeling in response to injury in a high-throughput in vitro platform.  Additionally, 
lower concentrations or different incubation methods could be used to study 
physiologically relevant effects of chelating agents, which has applications from studying 
nitric oxide pathways to optimizing dosing and drug combinations for treating 
atherosclerosis.  We also demonstrated that stimulation with inflammatory cytokines had 
detectable changes in endothelial permeability.  The large sample sizes and ease of 
fabrication makes this platform well-suited for studying dosing of inflammatory stimuli, 
as well as screening for vascular toxicity in compound libraries. Finally, as transport 
across the endothelial barrier is required for all drugs administered intravenously or 
absorbed through the gastrointestinal tract, this model system could be used to determine 
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Conclusions 
Our method for coating ECM-based microtissues with endothelial cells results in 
endothelium that interacts directly with a collagen tissue compartment – remodeling 
ECM via compaction as well as deposition of basement membrane proteins.  Although 
others have used microcarries to culture endothelial cells80,185,186, we have demonstrated, 
for the first time to the authors’ knoledge, high-throughput assessment of endothelial 
permeability on natural ECM, supporting robust statistical analysis. Streamlining our 
measuremnt furhter, we showed that widefield imaging is a viable method for semi-
quantitatively assessing endothelial macromolecular permeability for tissue-level 
measurments (compacted soft constructs) as well as for just the endothelium (stiff 
constructs).  Changes in dye exclusion were seen in our control conditions (acellular, 
coated, and EDTA treated); but more importantly, we can use our microtissue platform to 
detect changes in permeability with physiologically relevant stimuli. With these 
permeability measurements, we found that our platform recapitulates barrier function that 
is comparable to in vivo, which we hypothesize is due to the direct coupling of remodeled 
3D ECM with the endothelial cell layer.  
Our platform enables rapid fabrication (over 20,000 carriers produced per hour), 
quickly acquires images, and permits automated data analysis of our constructs. The 
miniaturization of the tissues also minimizes the cell number requirements, making this 
platform amenable to precious cell and ECM sources.  Moreover, because our growth 
conditions are compatible with standard cell culture equipment (e.g. multi-well plates), 
this method could be scaled up further and be integrated with automated liquid handling 
systems and automated imaging platforms. Overall, this platform recapitulates the 
functions of traditional transwell inserts, but affords novel application to high-throughput 
studies and opens up new possibilities for interrogating cell-cell and cell-matrix 
interactions. Permebility assays are not currently used for drug screens as no scalable 
platforms exist to make this measurement, making our platform an invaluable tool in 
studying how molecules enter the interstitial space and how they may affect sick or leaky 
vasculature. Potential applications also include detection of ECM deposition and 
remodeling in a high-throughput culturing platform, as well as studying specialized 
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endothelial and/or epithelial function in vitro -- including the blood-brain barrier. And 
due to the increased physiological relevance and the high-throughput nature of 
microtissues, our platform could facilitate screens for edematous agents or other 
modulators of endothelial permeability.Additionally, the use of widefield microscopy (as 
opposed to optical sectioning/confocal) and simple fabrication makes this platform more 
widely applicable and easier to disseminate to other labs for practical application of this 
measurement.  With the ease of fabrication, flexibility in cell type, and large sample 
sizes, this platform has a myriad of potential applications. 
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Figure 6.1: Fabrication of endothelial-coated collagen microtissues  
Liquid 6 mg/mL collagen I microtissues were generated using a chilled flow-focusing 
microfluidic device.  Microtissues were collected and polymerized off-chip at 25°C for 30 
minutes.  (a) In the case of “soft” microtissues, we did not need to further manipulate the collagen 
microtissues.  To coat with cells, microtissues were mixed with a single-cell suspension of 
endothelial cells.  In this “soft” mode, cells compacted the collagen microtissues.  (b) To prevent 
compaction, we created “stiff” microtissues.  After polymerization, microtissues were crosslinked 
with formalin.  “Stiff” microtissues were then washed thoroughly and coated by incubating with a 
single cell suspension of endothelial cells.  Cells created a monolayer on the surface of the 
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Figure 6.2: Endothelial cells formed confluent monolayers and remodel ECM-based 
microtissues   
Both soft and stiff microtissues were coated with endothelial cells and cultured for 5 days.  (a) On 
both soft and stiff microtissues, cells create confluent monolayers.  Cells in all conditions have 
characteristic morphology and tight-junction expression, visualized with CD31 and VE-cadherin.  
(b) Using immunofluorescence, we observed that the endothelial cells deposited Collagen IV and 
Laminin on the surface of the collagen constructs for both the soft and stiff conditions.  We 
qualitatively observed that (c) coating soft matrices with endothelial cells resulted in compaction, 
but (d) stiff matrices did not have a significant size change.  We quantified the projected area of 
the droplets before and after coating to quantify this result and found the population shift for the 
compaction to be extremely statistically significant, but observed no statistically significant 
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Figure 6.3: Second harmonic generation imaging reveals local remodeling of collagen 
architecture 
 Acellular collagen droplets were coated with endothelial cells and cultured for 5 days. (a) At 
intermediate timepoints, droplets were collected and imaged using Second Harmonic Generation 
(SHG) to visualize the collagen fibers.  (b) We observed that the average intensity of the soft 
microtissues on d1, d2, and d5 after coating with endothelial cells was significantly higher than 
acellular as well as the corresponding timepoints for the stiff tissues.  In (a), we observed a dense 
ring of collagen at the surface of the microtissues. (c) To quantify this, we took linescans from the 
center of the microtissues to the surface and recorded the image intensity along the line.  We 
repeated this 5 times for each droplet and reported a moving average with standard error of these 
linescans for each condition.  (d) Using these intensity profiles, we measured the distance into the 
droplet that displayed large differences in intensity (defined as 5-fold brighter than the baseline 
average on the d0 measurements).  We found that the stiff droplets showed very little remodeling 
of the interior of the droplet, but the soft constructs had large changes in intensity up to 97 µm 
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Figure 6.4: Microtissue endothelial barrier function is comparable to in vivo permeability 
 Endothelial cells were cultured on the surface of soft and stiff collagen microtissues for 5 days.  
Tissues were collected and some were treated with 5 mM EDTA for 30 minutes.  Constructs were 
placed in a 12.5 µg/mL dye bath and incubated for 20 minutes.  (a) Constructs were imaged with 
brightfield and optical sectioning. Brightfield imaging shows the location and geometry of the 
microtissues, nuclear stain confirms the presence of cells, and the movement 150 kDa TRITC-
Dextran was visualized with fluorescence microscopy. We qualitatively observe that acellular 
constructs do not impede dye movement, whereas the control condition showed exclusion of the 
dye from the interior of the microtissue for both the soft and stiff conditions.  The EDTA treated 
condition appeared to have an intermediated phenotype. Background noise was reduced in 
representative images for clarity. (b) We report the average droplet radius with standard error, 
showing that the soft constructs were compacted significantly, and the stiff constructs were 
largely unchanged in diameter. (c) Comparing the intensity inside and outside the droplet (ΔI), we 
found that ΔI was small for acellular constructs, and largest for coated constructs for both soft and 
stiff microtissues.  We found that the removal of the cell layer resulted in an intermediate ΔI for 
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both stiffnesses. (d) Converting the ΔI to the permeability using Eq. (3), we found the acellular 
constructs to have the largest permeability, and the coated controls to have a permeability that 
was statistically significantly smaller for both cases.  For the EDTA treated group, we found that 
this increased the average permeability for the stiff constructs in a statistically significant manner.  
There was a slight increase in the average also for the soft constructs, but this difference was not 
statistically significant.  We used these permeability values to calculate the contribution of the 
ECM and the cell layers individually and found the permeability of the cell layer to be on the 
order of 1x10-8 cm/s. All comparisons completed with one-way ANOVA with post-hoc Tukey 
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Figure 6.5: Endothelial barrier function can be assessed with widefield imaging for high-
throughput studies 
 Endothelial cells were cultured on the surface of collagen microtissues for 5 days before 
assessing permeability.  Constructs were soaked in 12.5 µg/mL bath of 150 kDa  fluorescent 
dextran.  Constructs were then imaged with widefield microscopy for the brightfield and 
fluorescent channels.  (a) To assess permeability, we used brightfield images to detect the 
centroid and edges of each microtissues and collected linescans from the center of the droplet to 
100 pixels outside the edge of the construct. (b) Representative images from acellular, control 
HUEC-coated, and 5 mM EDTA treated microtissues are shown. (c) When comparing the 
average microtissue radius (shown with standard error) for each condition, we observed 
consistent compaction of soft microtissues, and little change in size of stiff microtissues.  (d) To 
assess permeability, we calculated the difference in intensity between the outside and inside of 
the droplet (ΔI).  We observed that the acellular constructs were more saturated with dye in all 
construct conditions for both sizes of dye.  However, the cell monolayer demonstrated semi-
permeable qualities, which was especially visible on the stiff constructs. We found the addition of 
the cell layer increased ΔI for all conditions (p<0.01). In the large-soft and both stiff conditions, 
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the modulation of the cell layer with EDTA resulted in a statistically significant decrease in ΔI. 
When we tested inflammatory cytokines on our platform, TNF-α and TGF-β resulted in 
statistically signficant decreases in ΔI (relative to the coated control) for both sizes of stiff 
microtissues. From this, we concluded that the stiff microtissues were better suited for the 
macromolecular permeability assay (one-way ANOVA with post-hoc Tukey HSD test; p<0.01 = 
**, p<0.05 = *). Scale bars 100 µm. 
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Chapter 7 : Application –  Liver Micromimics  
Introduction 
One of the leading causes of preclinical and clinical drug attrition, post-market 
drug withdrawals, and acute liver failures is drug-induced liver injury (DILI)209. These 
failures are costly, both in terms of cost and time to successfully bring a new drug to 
market.  In an effort to streamline drug discovery and prioritizing lead compounds, there 
is increasing interest in predicting liver toxicity earlier in the drug development process.  
Because of species-specific differences in the liver’s metabolic pathways (e.g. drug 
metabolism)6,210, there is a need for predictive in vitro human liver models during the 
preclinical stages of drug development.   
A major challenge in creating in vitro systems is that the microenvironment in 
which cells are grown affects their function significantly.  The “gold standard” cell 
source are primary human hepatocytes (PHHs), isolated from human livers211.  Typically 
these cells are cultured on collagen-coated 2D multi-well plates for and the response to 
different drug concentrations is assessed using cell viability, morphology, and 
metabolism of substrates in the culture medium212,213.  Even with the addition of adsorbed 
ECM proteins, these platforms are unable to faithfully reproduce the 3D cell-ECM and 
cell-cell interactions found in physiology.  Additionally, long-term culture in these 
platforms can be challenging, as hepatocytes are prone to de-differentiate and apoptosis 
in traditional 2D culture212,213. Thus, there is interest in new model systems that 
incorporate a 3D microenvironment for the hepatocytes. 
A popular method for creating a 3D environment with a high density of cell-cell 
interactions for the hepatocytes is spheroid culture.  While self-assembled 3D spheroids 
mitigate some limitations of 2D cultures, this method is ineffective and fails for greater 
than 50% of PHH donor sourced cells.  Usually this is due to issues with structural 
stability, as the only ECM components in spheroids are produced by the hepatocytes and 
the rates of ECM secretion are variable across donors213,214.  To improve the structural 
stability of the constructs, encapsulating spheroids into bioinert agarose215 or 
poly(ethylene glycol)57,216 hydrogels has been tested, but neither provide 3D ECM 
interactions as occur in vivo.   
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To mimic the cell organization seen in vivo, others have used 3D bioprinting 
methods to create liver models.  Although these have several advantages as far as 
material choice and patterning of the cells, the final constructs are large (~mm in 
diameter) thus requiring large volumes of cells and reagents.  Ultimately, the large 
volumes of cells required for these large constructs constrains these platforms to low-
throughput applications61. Microfluidic liver-on-a-chip devices have also attempted to 
mitigate the previously discussed issues with liver model systems.  However, these 
systems remain low throughput, require complex fluid handling, use large amounts of 
often limited novel drugs via the tubing’s dead volume, and often layer 2D cell layers on 
membranes in lieu of a truly 3D cell culture63,67. Outside of the biological relevance, 
these chip setups are undesirable logistically for industry-scale drug screening and drug 
development as they are incompatible with high-throughput liquid handling systems 
typically used for large-scale screens70,211.  
The ideal in vitro human liver model is scalable, reproducible, modular, and 
displays long-term phenotypic stability at physiologically-relevant levels for elucidating 
the effects of chronic compound exposure as in humans; furthermore, the model needs to 
accessible within a culture format that is compatible with the established screening 
infrastructure in the pharmaceutical industry. To address this need, we adapted our 
microtissue platform to develop breakthrough 3D human liver microtissues and 
supportive fibroblasts that display the critical features necessary for drug development, 
including scalability, reproducibility, modularity, long-term phenotypic stability, and 
clinically-relevant utility for DILI assessment217.  In addition to drug screening, our 
platform is uniquely-suited to answer questions regarding 3D ECM interactions and their 
role on liver cell function in our constructs. We explore the modular nature of our liver 
microtissues workflow, performing a targeted-screen of combinations of ECM proteins in 
our liver microtissues.  We also use our platform for biological discovery, investigating 
the effect of combinations of liver-specific ECM proteins, as well as testing various cell 
sources for liver mimics including stem cell derived iHeps.  
 
Materials and Methods 
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Microfluidic and device fabrication 
Microfluidic devices were fabricated following the protocol in Chapters 3 and 5.  
Before use, tubing was sterilized with 70% ethanol and microfluidic devices were 
autoclaved to avoid contamination.   
 
Agarose Microwells 
Agarose microwells were fabricated following the protocol described in Chapter 
5.  After fabrication, agarose microwells were sterilized with 70% ethanol for 1 hour and 
washed extensively before use.  
 
Monoculture Microtissues  
Cell-laden microtissues were fabricated by modifying the protocol described in 
Chapter 3.  Briefly, a solution of rat tail collagen, type I (Corning Life Sciences, 
Tewksbury, MA) in acetic acid was first diluted in 1X phosphate buffered saline (PBS, 
Corning) to 6 mg/mL on ice, and then the pH was neutralized to 7.4-7.6 using 1N NaOH. 
Cryopreserved PHH (Lonza) or Induced Pluripotent Stem Cell–Derived Human 
Hepatocytes (iHeps; Cellular Dynamics International) were thawed, counted, and 
viability (>85%) was assessed as previously described218 and resuspended in the neutral 
collagen solution. Chilled ferromagnetic beads (Spherotech) were mixed into the collagen 
solution at a final concentration of 5% v/v.  The collagen solution containing cells was 
perfused into a flow-focusing microfluidic droplet generator inlet at 150 µL/hour in a 
cold room (4ºC) while fluorocarbon oil (FC-40, Sigma-Aldrich) with 2% 008-
fluoroSurfactant (RAN Biotechnologies, Beverly, MA) was perfused to produce collagen 
droplets.  Microtissues were collected in a 1.5 mL low-retention tube that was heated at 
37°C to promote collagen polymerization. Polymerized microtissues were washed with 
PBS, resuspended in culture medium, counted, and seeded into the agarose microwells 
within a 24-well plate (~600 microtissues/well). Culture medium, the composition of 
which was described previously219,220 was collected and replaced on microtissues every 4 
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Co-cultures of PHHs and 3T3-J2 murine embryonic fibroblasts 
3T3-J2 fibroblasts were growth arrested by incubating with 1 µg/mL mitomycin-C 
(Sigma-Aldrich, St. Louis, MO) in culture medium for 4 hours prior to detachment from 
the culture substrates using trypsin as previously described221. PHH monoculture 
microtissues were fabricated, counted, and placed into agarose microwells within a 24-
well plate. 3T3-J2 fibroblasts were then seeded onto the polymerized PHH microtissues 
at ~1:1 PHH to fibroblast ratio. The fibroblasts preferentially attached to the collagen 
microtissues as opposed to the non-adhesive agarose to coat co-culture microtissues. 
Culture medium was collected and replaced as described above for monocultures.  
 
Hepatocyte functional assessments 
Culture supernatants were assayed for albumin using a sandwich enzyme-linked 
immunosorbent assay (ELISA, Bethyl Laboratories) with horseradish peroxidase 
detection and 3,3’,5,5’-tetramethylbenzidine (TMB, Rockland Immunochemicals, 
Boyertown) as the substrate221. Absorbance values were quantified on the Synergy H1 
multi-mode plate reader (BioTek).  
Cytochrome P450 (CYP450) 3A4 and 2C9 enzyme activities were measured by 
incubating the cultures with luciferin-IPA or luciferin-H substrates (Promega Life 
Sciences, Madison, WI), respectively. The metabolite, luciferin, was quantified via 
luminescence detection on the Synergy H1 multi-mode plate reader according to 
manufacturer’s protocols. CYP1A2 and CYP2A6 activities were measured by incubating 
the cultures with 5 µM 7-ethoxyresorufin or 50 µM coumarin (Sigma-Aldrich), 
respectively. The metabolites, resorufin and 7-hydroxycoumarin (7-HC), generated from 
7-ethoxyresorufin and coumarin, respectively, were quantified via fluorescence detection 
(excitation/emission: 550/585 nm for resorufin, and 355/460 nm for 7-HC) on a Synergy 
H1 multi-mode plate reader220.  Substrates were incubated in cultures for 3 hours for 
PHH cultures, and 2 days for trials using iHeps. 
 
Encapsulating rhodamine-labeled laminin in microtissues 
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Rhodamine-labeled laminin (Cytoskeleton, Inc) was mixed into 6 mg/mL collagen 
solution at 4C to a final concentration of 10 µg/mL.  Microtissues were fabricated, 
polymerized, and samples were moved to 96-well plates before breaking the emulsion.  
Time-lapse widefield imaging was used to track the movement of rhodamine-labeled 
laminin before and after breaking the emulsion with PBS.   
 
Supplementing culture media with proteins of interest 
Complete culture media for PHHs and iHeps was prepared as described previously219,220.  
Proteins of interest were stored at manufacturer recommended temperatures, and were 
added to cold media before warming to 37°C and adding to microtissues. Human laminin 
(Sigma), fibronectin (VWR), collagen III (Sigma), and collagen IV (Sigma) were added 
to final concentrations of 10 µg/mL and media on cultures was replaced every 4 days. 
 
Data analysis 
Data processing was performed using Microsoft Excel and image analysis was performed 
using ImageJ84. GraphPad Prism (La Jolla, CA) was used to display results. Mean and 
standard deviation are displayed for all data sets.  Statistical significance was determined 
using Mann-Whitney U test, one-way ANOVA followed by a Tukey-Kramer HSD post-
hoc test (p< 0.05). 
 
Results 
Droplet microfluidics for generating reproducible and functional PHH microtissues  
In this adaptation for liver-specific applications, we modified the workflow 
described in Chapter 5.  PHH microtissues were fabricated using flow-focusing droplet 
microfluidics and seeded into agarose microwells within industry-standard 24-well plates 
as illustrated in Figure 7.1. Highly reproducible microtissues were fabricated and cultured 
for 21 days.  
 
3T3-J2 murine embryonic fibroblasts enhance PHH functions in microtissues 
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3T3-J2 fibroblasts are known to enhance PHH functions in both 2D co-cultures221 
and 3D self-assembled spheroids222. PHHs and growth-arrested 3T3-J2 fibroblasts (1:1) 
were coated onto the surface of the collagen-based PHH microtissues and compared to 
PHH-only (control) microtissues (Figure 7.2a). Supporting previous results with PHH 
cultures in our microtissue system217, coated microtissues functionally outperformed 
monoculture microtissues, as indicated by at least a 1.6-fold increase in albumin secretion 
and CYP450 activity.  Specifically for albumin, coated microtissues outperformed PHH-
only microtissues by 1.6- and 7.6-fold at 5 and 21 days (Figure 7.2b). For CYP3A4, 
coated microtissues outperformed monoculture constructs by 1.6-, 11.7- and 25.1 fold 
after 5, 13, and 21 days, respectively (Figure 7.2c). For CYP2A6, coated microtissues 
outperformed PHH-only microtissues by 6.4- and 7.4-fold after 13 and 21 days, 
respectively (Figure 7.2d). For CYP2C9, coated microtissues outperformed PHH-only 
microtissues by 19- and 14-fold after 9 and 17 days (Figure 7.2e). Lastly, for CYP1A2, 
coated microtissues outperformed PHH-only microtissues by 1.6-fold after 9 days (Figure 
7.2f).  
 
Validating methods for doping ECM proteins in collagen microtissues 
While a variety of natural ECM materials are compatible with hepatocyte 
culture215,223, rat tail collagen I was selected for our initial model system since it is 
abundantly and cheaply available at high concentrations needed for gelation (>2 mg/mL) 
and has been utilized extensively for PHH culture without adverse effects215,219. The 
ECM of the liver, though, is much more complex, including a wide range of collagen 
proteins (including collagen types I, III, IV, and V224–226) as well as glycoproteins (such 
as laminin, fibronectin, tenascin, and nidogen226) and proteoglycans (including heparin, 
dermatan, chondroitin sulphate, perlecan, hyaluronic acid, biglycan and decorin227).   
To study the effects of other ECM proteins, we first optimized a method for 
incorporating supplemental ECM proteins into our microtissue constructs. We initially 
used rhodamine-labeled laminin as a tracer molecue to visualize the movement and final 
location of supplemented protein in our setup.  Constructs were doped with 10 µg/mL 
rhodamine-labeled laminin before polymerization (Figure 7.3a), rhodamine-labeled 
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laminin was easily detected in polymerized microtissues still in the FC-40 oil emulsion.  
However, after breaking the emulsion with an aqueous phase, the protein escaped the 
microtissue and the concentration within the microtissue was reduced significantly after 
only 10 minutes (Figure 7.3a).  Alternatively, we soaked acellular microtissues in media 
with 10 µg/mL laminin or 10 µg/mL fibronectin and using immunofluorescence staining, 
found that these constructs had detectable levels of the proteins of interest after 24 hours 
(data not shown).  The fluoresence intensity stabilized after 5 days (Figure 7.3b), and was 
verified for long-term culture (21 days, data not shown) .  
 
Targeted ECM screen on PHH-laden microtissues 
 We have observed that PHHs survive and are functionally stable for at least 3 
weeks in our system using only collagen I as the construct ECM. We hypothesized that 
including more of the complexity of the in vivo liver ECM in our model system may 
improve the performance of hepatocytes in our platform.  We supplemented our collagen 
I constructs with laminin, fibronectin, collagen III, and collagen IV in various 
combinations (+ALL with all 5 proteins, and +ALL condition minus one protein only) 
and cultured the constructs for 21 days.  Using immunofluoresence, we visualized the 
albumin in our constructs for all conditions tested for PHH monoculture (Figure 7.4a) and 
PHH co-culture with 3T3-J2 (Figure 7.4b).  As observed previously with ELISA, the 
staining revealed increased albumin staining intensity with co-culture with 3T3-J2 cells 
for the control collagen I constructs.  Within the monoculture and co-culture groups, 
however, no tested supplemental ECMs resulted in statistically significant increases in 
fluoresence intensity outside the range of the assay defined by the controls.  
 We continued our assessment of PHH function via quantification of secreted 
proteins and CYP450 enzyme activity with ELISA (controls run in duplicate).  In the 
PHH monoculture microtissues, we observed similar responses (no statistically 
significant differences) between the control (collagen I) and supplemented ECM protein 
conditions, with a steady decline in albumin secretion (Figure 7.4b) and activity of 
CYP3A4 (Figure 7.4c), CYP1A2 (Figure 7.5c), CYP2A6 (data not shown), and CYP2C9 
(data not shown) for all conditions tested. For the co-culture conditions of PHH and 3T3-
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J2s (Figure 7.5b-d), we again observed similar performance (no statistically significant 
differences) between the collagen I controls and any conditions with supplemented 
protein. From both the immunofluorescense and ELISA readouts (Figure 7.5), no tested 
combinations of ECM produced a significant increase or decrease in PHH function in our 
platform outsdie the range of the assay defined by the controls. This trend was true for 
both coated and uncoated conditions.  
 
Targeted ECM screen on iHep-laden microtissues 
 Although PHH perform well in specific in vitro models, PHHs are a severely 
limited resource and there can be significant variability in the quality of cells between 
donors.  Thus, there is interest in pursuing other cell sources, and induced Pluripotent 
Stem Cell–Derived Human Hepatocytes (iHeps) have the potential to be: (i) adequately 
scalable for large-scale compound screens, and (ii) serve as a patient-specific cell source, 
facilitating toxicity screens for individual patients228–232.  We examined the performance 
of iHeps in our microtissues, and assessed the impact of supplemental ECM proteins on 
these cultures. 
Based on previous work220, we cultured all conditions in the presence of 3T3-J2 
cells. We performed a similar targeted ECM screen, soaking iHep-laden collagen I 
constructs with laminin, fibronectin, collagen III, and collagen IV individually, as well as 
all 5 of these proteins simultaneously (+ALL).  We used immunofluorescence to 
visualize albumin in the constructs after 32 days of culture (Figure 7.6a). We observed 
more heterogeneity in the cell morphology with the iHeps than with the PHHs.  With the 
exception of the +Laminin and +ALL conditions, two distinct morphologies were single 
cell distributions of cells that were weakly positive for albumin, and clusters of cells that 
were strongly positive for albumin. For the + Laminin and +ALL conditions, only the 
single-cell distribution that stained weakly for albumin was observed.   
These qualitative differences in morphology and immunofluorescence staining were 
reflected in the quantitative functional readouts.  Quantifying albumin production with 
ELISA over the timecourse of the experiment (Figure 7.6b), we observe an extremely 
significant decrease in albumin production for the +Laminin condition (p<0.0001) and a 
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significant decrease for the +ALL condition (p<0.001) relative to the control condition 
(collagen I only).  This trend continued for the CYP functionality tested, reflected in 
CYP3A4 (Figure 7.6c), CYP1A2 (Figure 7.6d), and CYP2C9 (Figure 7.6e).  We also 
examined alpha-fetoprotein (AFP) levels as an indicator of iHep maturity, and found no 
clear increase or decrease in AFP concentration (Figure 7.6f).  
 
Discussion 
An ongoing challenge for assessing the effects on the liver of chronic compound 
exposure in vitro is the lack of a model system that is scalable, reproducible, modular, 
and supports long-lasting organotypic liver function.  In this study, we adapted our 
collagen microtissues platform to create human liver microtissues in a 3D ECM-based 
microenvironment. Further, culture of the microtissues within agarose microwells in 
industry-standard multiwall plates makes this technology more relevant for real-life 
application of toxicity screening. 
It has been shown previously that the cell-cell interactions between hepatocytes 
and NPC types can affect hepatocyte function in developing and adult livers215,223. For 
our in vitro model, we replicated this effect by co-culture with 3T3-J2 murine embryonic 
fibroblasts233, as this line (over other potential choices such as human liver sinusoidal 
endothelial cells219, hepatic stellate cells234, and Kupffer cells235)  has been shown to 
induce higher PHH functions in 2D co-c ultures221. In our 3D culture system, we 
observed that the fibroblasts enhanced PHH functions over PHH mono-cultures. 
Examining albumin and urea secretion as well as activity of multiple CYP450 
isoenzymes, we found the coated microtissues displayed long-term phenotypic 
function217. Such enhanced longevity could enable the elucidation of the chronic effects 
of drugs, industrial chemicals, and disease stimuli on PHH functions. 
We further hypothesized that our modular microtissues would be uniquely suited 
for 3D ECM screens.  We first optimized a method to incorporate supplemental ECM 
proteins into collagen I microtissues. We investigated first the most reagent-conservative 
approach of doping the proteins in with the liquid collagen solution before microtissue 
fabrication.  We found that the supplemental protein was compatible with our fabrication 
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process, as signal from our tracer protein (rhodamine-labeled laminin) was distributed 
evenly in collagen microtissues while still in the oil phase.  However, shortly after 
breaking the emulsion (~10 minutes) the supplemented protein was evenly distributed in 
all of the aqueous phase and was not confined or concentrated in the droplet space.  This 
is likely due to the highly porous nature of collagen I hydrogels, which have a mesh size 
of ~ 1 µm77, which is too large to contain our supplemental proteins of interest (~400-
900kDa) by confinement.     
A second approach to incorporate other ECM proteins into our collagen I 
constructs was to supplement the culture media with the proteins of interest and allow 
them to diffuse into the constructs.  We found that soaking constructs in protein-
supplemented media resulted in detectable levels of protein in the constructs after 24 
hours, with saturation of the constructs being reached after 5 days. From a logistics 
standpoint, this method of incorporating supplemental protein has several advantages.  
Because all of the replicates for all conditions are fabricated from the same run of 
microtissues, potential variation in cell handling, collagen solutions, and polymerization 
conditions are controlled between conditions.  And for cases where cells are a precious 
resource, this method requires only one droplet setup to fabricate tens of thousands of 
microtissues, reducing waste from dead volume in the system.   
 Using our optimized method, we augmented collagen I constructs with additional 
liver-inspired ECM molecules such as other collagens (e.g. collagen III, collagen IV), 
fibronectin, and laminin. We confirmed that our scaled-up version of the experiment was 
still successful, as our collagen I control constructs had a strong response to co-culture 
with 3T3-J2 cells, with albumin production and CYP activity improving over the course 
of the 21-day experiment.  The stability of these constructs is imperative for studies of 
chronic drug toxicity and biological discovery of phenomenon that take time to develop. 
Examining the effects of supplemented ECM proteins on PHH monocultures, we 
hypothesized that the addition of these ECM proteins may improve hepatocyte function 
in vitro even in the absence of the supporting cell layer.  We found, though, that none of 
the combinations of proteins tested resulted in a statistically significant change in 
function when quantified with the described assays. Running the same ECM screen in the 
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presence of the supporting 3T3-J2 cell layer, we also did not find any combinations of 
ECM that improved or diminished PHH function in a meaningful way.  These results 
indicate that the effect of the supporting cell type is not replicated solely by the 
introduction of more ECM proteins and while incorporating more of the complexity of 
the in vivo liver in our model, we may be more interested in investigating cell-cell 
interactions for future studies.   
We completed a targeted ECM screen also with an alternative cell source – 
human stem-cell derived cells (iHeps). We observed albumin secretion and CYPP450 
enzyme activity for iHeps encapsulated in collagen I with surface-coating of 3T3-J2 cells.  
Examining the supplemental ECM protein conditions, we conclude from our results that 
the presence of supplemented laminin (even with other supplemented ECM proteins) 
interferes with several key functions of iHeps in our model system.  We observed 
morphologically that culture conditions with supplemented laminin failed to form clusters 
of cells and instead remained as single cells in the constructs.  It is known that homotypic 
interactions are important for iHep viability and function in vitro220, so this difference in 
cell patterning within the microtissues may be the cause of the poor cell performance and 
warrants further investigation. Finding the ideal culture conditions for iHeps in our 
system could be extremely valuable, as this cell source is both scalable and patient-
specific228–232, potentially facilitating personalized screening for off-target effects (e.g. 
liver toxicity) in the future.  
We demonstrate that our platform supports 3D culture of human liver cells (PHH) 
and stem cell derived liver-like cells (iHeps).  Cells display phenotypic stability, 
including CYP450 enzyme activities, for 3 weeks, and can be used within industry-
standard multiwell plates to assess clinically-relevant compound metabolism and toxicity.  
We also demonstrate the potential for this platform for ECM screens, and similar 
experiments could be scaled up and conducted for compound screens.  Ultimately, this 
platform can serve to reduce drug attrition, enable the screening of molecules to optimize 
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Figure 7.1: 3D human liver tissue platform with tunable cell-cell and cell-ECM interactions 
for compound screening  
(a) Hepatocytes are suspended in pH-neutralized collagen solution and then perfused through a 
flow-focusing microfluidic device. Oil is perfused at a rate ~4 times faster than the aqueous phase 
to produce microtissues. Microtissues are formed using the microfluidic device at 4°C and 
collected at 37°C to promote the rapid polymerization of the collagen droplets and encapsulation 
of the cells within the droplets. Oil is removed, and polymerized microtissues are resuspended in 
culture medium and subsequently seeded into agarose (2% w/v) microwells cast within multi-well 
plates. (b) The hepatocytes are co-cultured with non-parenchymal cell types, such as 3T3-J2 
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Figure 7.2: Co-culture of PHHs with 3T3-J2 mouse embryonic fibroblasts in microtissues 
enhances liver functions 
 (a) Brightfield images for tested culture models (monoculture and co-culture coated with 3T3-J2 
cells). (b) Albumin secretions throughout the 21 day experiment. Activities of different CYP450 
isoenzymes, (c) CYP3A4, (d) CYP2A6, (e) CYP2C9, (f) CYP1A2 in PHH-only (control) and 
coated microtissues. Statistical significance is displayed for coated microtissues relative to co-
encapsulated microtissues (***p ≤ 0.001, and ****p ≤ 0.0001). 
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Figure 7.3: Validation of methods for incorporating ECM proteins into collagen I microtissues 
We initially tested incorporating ECM proteins into the chilled collagen solution before 
compartmentalization into individual microtissues (a).  We observe that the protein is clearly 
within the droplets while still in the oil phase.  However, shortly after breaking the emulsion with 
cell culture media, the supplemented protein is no longer contained within the droplet.  We also 
examined soaking polymerized collagen I microtissues in a bath of supplemental protein (b).  We 
observe that for our proteins of interest, detectable levels of protein are discernable within the 
microtissue constructs after 24 hours, with optimal saturation of protein achieved after several 
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Figure 7.4: Targeted ECM screen for PHH monocultures in microtissues 
 Immunofluoresence stining (a) for albumin (green) and nuclei (Hoechst, blue) show similar 
construct morphology and albumin production between all protein combinations tested.  
Examining the protein function with secreted albumin (b), we obsrve that the PHH monocoulture 
controls (collagen I, red) show a sharp decline from d5 to d9, and maintain low levels of activity 
throughought the remainder of the 21 day experiment.  We observe similar performance for all 
supplemented ECM conditions tested for the PHH monoculture constructs. Examining CYP3A4 
(c) and CYP1A2 (d) activity other indicators of PHH function, we observe no statistically 
significant differences in substrate metabolism between the controls (red) and any of the ECM 
conditions tested, with a steady decline in metabolism for all conditions.  Error bars represent 
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Figure 7.5: Targeted ECM screen for co-culture of PHH and 3T3-J2s in microtissues  
Immunofluoresence stining (a) for albumin (green) and nuclei (Hoechst, blue) show similar 
construct morphology and albumin production between all protein combinations tested.  
Examining the protein function with secreted albumin (b), we obsrve that the PHH co-ocoulture 
with 3T3-J2 controls (collagen I, red) show a gradual increase in albumin production from d5 to 
d21. There were, however, no ECM conditions that improved or diminished albumin production 
outside the range of the control replicates (red). Examining CYP3A4 (c) and CYP1A2 (d) activity 
as other indicators of PHH function, we observe a trend of increased activity over time with no 
statistically significant differences in substrate metabolism between the controls and any of the 
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Figure 7.6: Targeted ECM screen for co-culture of iHeps and 3T3-J2s in microtissues  
Immunofluorescence staining (a) for albumin (green) and nuclei (Hoeschst, blue) show 
heterogeneity in cell morphology within most of the ECM conditions examined.  Constructs 
began as single cell suspensions, and all conditions had some microtissues that retained this 
patterning of cells (low albumin signal).  In all conditions tested except for +Laminin and +ALL, 
we qualitatively observe spheroid growth with high intensity of albumin staining (high albumin 
signal).  Quantifying albumin production with ELISA over the timecourse of the experiment (b), 
we observe an extremely significant decrease in albumin production for the +Laminin condition 
and a significant decrease for the +ALL condition relative to the control condition replicates 
(collagen I only).  This trend continued for the CYP450 enzyme activities tested, reflected in 
CYP3A4 (c), CYP1A2 (d), and CYP2C9 (e).  We also examined AFP levels as an indicator of 
iHep maturity, and found no clear trends.  All error bars report standard deviation.  Scale bars are 
100 µm.   
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Chapter 8: Cryopreservation of Collagen Microtissues 
This chapter contains material from “A High-Throughput Workflow to Study 
Remodeling of ECM-Based Microtissues” by Alexandra L. Crampton*, Katherine A. 
Cummins*, and David K. Wood. Tissue Engineering Part C: Methods, volume 25, issue 
1, pages 25-36, 2019; permission conveyed through Mary Ann Liebert, Inc., New 
Rochelle, NY. *These authors contributed equally. 
 
Introduction 
One of the foundations of tissue engineering and in vitro model development is the 
ability to cryopreserve cells while minimally affecting viability and function upon 
thawing.  For tissue engineering applications, cryopreservation is a prevelent method of 
providing a continuous source of cells236–238.  Cryopreservation parameters are optimized 
for each cell type, but generally these methods begin with transferring cells to a chilled 
cryoprotective solution239, slowing cell metabolism and minimizing toxicity of the 
cryoprotective agents238.  The temperature of the cells is reduced further at a specific 
freezing rate240,241 and cryopresrved cells are stored at subzero temperatures.  Cells are 
then thawed and cryoprotective agent are removed before use242.  
A major challenge in any cryopreservation protocol is the delicate balance between 
cryoinjury and cytotoxic effects of cryoprotective agents243.  The mechanism of action for 
cryoprotectants varies, but the overall effect is protection of the structures of the cells due 
to state change of water at low temperatures (<0 C). These protective qualities, though, 
are temperature-dependent, resulting in cytotoxicity if the thawing and/or removal of the 
cryoprotective agents is too slow236–238.  Cryopreservation of larger constructs becomes 
more challenging238,244,245; however, we hypotheisze that the small-size scale and highly 
porous nature of our collagen microtissues may make these constructs amenable to 
standard cryopreservation protocols.  
We aimed to assess efficacy of cryopreservation of microtissue constructs. We 
anticipate that our workflow would be improved if we could “pause” the experiment after 
fabriation of the tissues (Figure 8.1).  This would facilitate use of microtissues from a 
single fabrication setup across several experiments over time, avoid waste, and improve 
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distribution of samples to off-site labs. To validate cryopreservation with our platform, 
we compare functional readouts such as viability, proliferation, compaction, and liver-
specific functions of microtissues containing various cell types before and after freezing.  
 
Materials and methods:  
Cryopreservation 
Microtissues were resuspended in freezing solution (90% FBS + 10% DMSO or 
Cryostore CS10 (BioLife Solutions)) and frozen in 500 µL aliquots. Tissues were cooled 
gently (-1°C/minute) using a Mr. Frosty (Thermo Scientific) overnight and then 
transferred to liquid nitrogen for 1 week. Control tissues from the same experiment were 
pipetted into plates containing microwells immediately after fabrication to compare the 
effects of freezing. 
 
Thawing of cryopreserved microtissues 
 Microtissues were moved from liquid nitrogen storage and thawed for 2 minutes 
in a 37°C water bath.  Microtissues in freezing media were diluted in warm media in a 50 
mL conical tube and allowed to settle for 5 mintues.  Supernatant was aspirated and 
additional warm media was added to the microtissues to further dilute the cryoprotectant.  
Microtissues again settled for 5 mintues before being distributed into plates for 
experiments.  Constructs were optionally coated with 3T3-J2 fibroblasts for co-culture 
conditions, following the protocol detailed in Chapter 7.2 Methods.  NIH 3T3 cells, 
MDA-MB 231 cells, and NHLF were cultured under conditions described in Chapter 5 
for 1 week.   HepG2 liver carcinoma cells were cultured in DMEM with 10% bovine 
serum (Gibco) and cultured for 2 weeks. 
 
Viability and proliferation staining  
Following the protocol outlined in Chapter 5, at various timepoints, tissues were 
gently pipetted and removed from microwells and collected in an Eppendorf tube. 
Constructs were washed thoroughly with DPBS and then incubated with a staining 
solution of 5 µM DRAQ5 (Invitrogen) and 5 µM Calcein AM at 37°C for 20 minutes. A 
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Zeiss Axio Observer was used to image each microtissue and images were analyzed to 
count the total number of cells (from the nuclear stain) and the number of live cells (from 
the Calcein) for each microtissue.  
To visualize proliferation, microtissues were incubated for 4 hours with 10 µM 5-
ethynyl-2’-deoxyuridine (EdU) before fixing with 3.7% formalin and a Click-iT EdU 
Alexa Fluor 647 kit (Invitrogen) was used following manufacturer’s instructions. A Zeiss 
Axio Observer was used to image z-positions throughout each microtissue with a step 
size of 10 µm. At least 28 microtissues were examined for each condition. 
 
Immunofluorescence staining 
Tissues were stained following the potocol outlined in Chapter 5. Briefly, 
microtissues were collected in low-retention Eppendorf tubes and fixed with 3.7% 
formalin overnight at 4°C. Constructs were blocked and permeabilized with 10% FBS 
and 0.1% Triton X-100 for 1 hour at room temperature. The tissues were then incubated 
with primary antibody (rabbit anti-albumin (1:1000, Rockland) at 4°C overnight. The 
microtissues were washed thoroughly, and incubated with secondary antibody (1:500, 
Jackson) at 4°C overnight. A Zeiss Axio Observer was used to obtain widefield 
fluorescence images of constructs. 
 
ELISA for CYP2A6 activity 
Following the protocol described in Chapter 7, cytochrome P450 (CYP450) 2A6 
activities were measured by incubating the cultures with 50 µM coumarin (Sigma-
Aldrich). The concentration of metabolite, 7-HC, generated from coumarin was 
quantified via fluorescence detection (excitation/emission: 355/460 nm) on the Synergy 
H1 multi-mode plate reader220.  Substrates were incubated in cultures for 2 days for trials 




Cell-laden microtissues retain high viability after cryopreservation 
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Cryopreservation is important for preserving precious cell populations and, as an 
experimental tool, maximizes the number of experiments that can be completed out of a 
single cell source. Freezing large tissues is challenging because diffusion limitations 
prevent cryoprotectants from fully penetrating the tissue and results in damage during 
freezing. However, the small size scale of our microtissues allows for sufficient transport 
of cryoprotectant necessary for freezing while retaining the ability to study tissue-level 
functions. 
To assess the compatibility of our microtissues with cryopreservation protocols, 
we first cultured NIH 3T3 cells, MDA-MB 231 cells, and NHLFs on tissue culture plastic 
following cell distributor instructions.  We used these cells to fabricate cell-laden 
microtissues with 6 mg/mL collagen. Immediately after microtissue fabrication, we 
cultured half of our microtissues following standard protocols and cryopreserved the 
remainder using cell distributor recommended freezing solutions. Cryopreserved NIH 
3T3, MDA-MB-231, and NHLF cells encapsulated in 6 mg/mL collagen microtissues 
demonstrated high viability 1 day after thawing (84, 87, and 83% respectively), which 
was similar to their controls (86, 94, and 90%). The percentage of live cells improved 
after a week of culture (92, 98, and 88%) (Figure 8.2a), which was also similar to the 
corresponding controls (90, 97, and 89%), with viability at the 2 week timepoint 
remaining similarly high (data not shown). 
 
Cells retain their ability to remodel ECM and to proliferate after encapsulation and 
cryopreservation in microtissues 
It is known that cryopreservation processes can alter cells dramatically, so 
maintaining cell functionality in addition to high viability  is imperative for successful 
cryopreservation in this platform.  Thus, we further assessed cell function after 
cryopreservation through a compaction  and proliferation assay. To determine the 
difference in compaction between control and frozen tissues, we compared final 
microtissue diameters for each condition and found them to be insignificantly different 
(p>0.05) (Figure 8.2b). We also observed that at intermediate timepoints each cell type 
demonstrated similar compaction between cryopreserved and control microtissues. 
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Lastly, in addition to retaining contractile function, all three cell types retained 
proliferative ability after freezing, as all microtissues in every condition tested had cells 
that entered S phase (Figure 8.2c).  
 
Liver carcinoma cells continue to secrete albumin and demonstrate CYP3A4 activity 
after cryopreservation in microtissues 
Cryopreservation of cell-laden microtissues has distinct advantages for making 
the most out of precious cell sources that need 3D environments to maximize their 
efficacy in vitro.  A specific example are liver cells since they thrive in the 3D 
microenvironment of the collagen microtissues, but we often will not fully utilize all of 
the tissues fabricated for a single experiment.  To get the most out of these expensive and 
precious resources, we explored the compatibility of liver-derived cells with 
cryopresrvation in collagen microtissues.   
 Given our success with cancer cell lines, we opted first to explore cryoprervation 
of liver cells with a liver carcinoma line – HepG2. One of the challenges we anticipate 
facing with primary liver cells is that the cells will undergo two thawing steps in a 
relatively short period of time, as cells are thawed on the microtissue fabrication day, 
cryopreserved once encapsulated in microtissues, and thawed again for future use in 
experiments.  To address this potential new workflow, we used HepG2 to test our 
cryopreservation protocol with cells that were thawed immediately before encapsulation 
and re-cryopreservation.  We observed that HepG2 had similar viability regardless of the 
preparation of cells before encapsulation and cryopreservation (>95% for both cases).  
Based on these results, we proceeded with encapsulating cells immediately after thawing 
from cryo storage for all following experiments. 
 We then examined function of these constructs for liver-specific readouts.  We 
visualized albumin in our constructs at the end of the culture period (d13) with 
immunofluoresence staining (Figure 8.3a).  We confirmed that constructs that were not 
cryopreserved showed strong albumin staining after 13 days of culture with and without a 
supporting fibroblast (3T3-J2) layer (Figure 8.3a).  We used these albumin production 
levels as a target for all other treatment conditions.  We then tested two cryopreservation 
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solutions – FBS+10%DMSO and Cryostor CS10 – as the former was shown to work well 
in our system with other cell types, and the latter has been shown to improve viability and 
function of cryopreserved hepatocytes246,247. In all conditions tested (including the 
control), we observed three main phenotypes for microtissues after 13 days of culture: 
microtissues with 1) low cell number and single-cell distribution, 2) small clusters of 
cells, or infrequently 3) dense growth of cells that overgrows the original size of the 
microtissue. We did note that the addition of the supporting 3T3-J2 layer did increase the 
intensity of albumin staining, but the result was not as profound as for previously tested 
primary hepatocytes in microtissues (Figure 7.2, 7.4, 7.5 and Kukla et al.217).  
Additionally, the 3T3-J2 layer did not resolve the microtissue heterogeneity for any 
condition tested. Comparing the morphology and intensity of albumin staining to the 
controls after two weeks of culture we observed that the Cryostor CS10 had less impact 
on cell growth and organization in the co-culture condition than the mono-culture 
condition (Figure 8.3a). We also observed that the FBS/DMSO solution resulted in 
similar albumin staining for both the monoculture and co-culture conditions.  
 To quantify these observations, we assessed CYP2A6 function with ELISA.  We 
observed that freezing these microtissues did not negatively impact CYP2A6 function 
since both cryoprotectants resulted in CYP2A6 activity that was equal or greater than the 
never-frozen control (Figure 8.3 b,c).  We also again note that the improvement from co-
culture with 3T3-J2s was not as pronounced with the HepG2 cell line as with previously 
tested PHHs215,219 and iHeps220, but was still statistically significant for the control (d13, 
p-val = 0.0028) and the CryostorCS10 condition (d9, p-val = .0076; d13, p-val < 0.0001).  
For the FBS/DMSO solution, there was no statistically significant change in CYP2A6 
function with the addition of the 3T3-J2 cell layer.  
 
Discussion:  
Here, we present proof-of-concept that microtissues can be easily cryopreserved 
with methods typically used for single cell suspensions. The use of standard tissue culture 
cryopreservation protocols for a whole-construct application is unusual as diffusion 
limitations typically prevent the use of DMSO, as large tissues are difficult to saturate 
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efficiently. PEG is an extremely popular material for cell encapsulation, but transport 
limitations in these systems are severe, with pore sizes of the hydrogels ranging from ~40 
to 200 Å76. This is a stark contrast to collagen gels that have pore sizes > 1 µm77. Because 
our tissue constructs are small and highly porous, we can use a range of cryoprotectants 
not usually available for whole tissue constructs, as we can quickly saturate the tissues 
with cryoprotectant agents and avoid deleterious effects238. Combined with the ability to 
cryopreserve the constructs, we can preserve precious cell populations to maximize the 
timescale and number of experiments that can be completed with a single cell source. 
Succuessful cryopreservation protcols preserve both the viability as well as 
function of the cell upon thawing. We confirmed that after cryopreservation and 
subsequent thawing of microtissues, encapsulated cells are have high viablity 
immediately after thawing as well as after one week of culture, comparable to never-
frozen controls. To assess cell function after cryopreservation, we examined gel 
contraction and proliferation.  We observed that construct contraction and proliferation 
was similar to controls for all cell types tested.  We validated this protocol with mouse 
fibroblasts (NIH-3T3), human cancer line (MDA-MB-231), and human lung fibroblast 
(NHLF), confirming that cryopreservation of microtissues is effictive with a range of cell 
sources.  
We continued to explore the specific application of whole-construct 
cryopreservation with liver carcinoma cells (HepG2).  As we previously found with other 
liver cell types215,219,220, HepG2 have improved function (albumin and CYP2A6 activity) 
in co-culture with 3T3-J2 cells.  Unlike PHHs, HepG2s do not show functional decline as 
a monoculture, which may make them a simplified, preliminary model despite the 
increaesd construct heterogenity with long-term culture. The positive staining for 
albumin in all conditions tested as well as detectable levels of CYP2A6 activity is 
encouraging, and motivates us to continue optimizing this protocol for use with primary 
cells (PHH).  
With these HepG2 tissues, we also compared two cryopreservation media 
formulations – FBS/DMSO and Cryostor CS10.  DMSO has been shown to have 
cytotoxic effects above tempratures of 10C238,243, so we compared an alternative 
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cryopreservation medium that has precedent in the field for cryopreservation of 
hepatocytes246,247.  For HepG2, we found that the functional improvement with the co-
culture of 3T3-J2 was only observed with Cryostor CS10, making this our preferred 
choice for liver-specific assays.   
We did observe heterogeneous phenotypes of HepG2 constructs after extended 
culture.  Heterogeneity in microtissues is not necessarily a negative quality, and may 
infact better represent the heterogeniety in the cancer line itself.  This parameter, 
however, does need to be accounted for to determine adequately large sample sizes for  
treatment conditions. 
Cryopreservation is the best way to make the most of precious cell sources since 
microtissues are produced in such large quantities that--especially for biological 
discovery and protocol development – they cannot all be used effectively in a single 
experiment.  This also promotes the dissemination of this technology since only standard 
cell culture plates and reagents are required to culture the microtissues after fabrication.  
In the case of receiving patient samples that cannot be duplicated, this cryopreservation 
protocol allows experiments to be spread across labs and timepoints.  We are eager to 
continue optimizing this protocol and to epxand our experiments to include primary cells  
(including PHH) in the near future.  
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Figure 8.1: Cryopreservation adds flexibility to our microtissue-microwell workflow  
With the addition of cryopreservation to our previous workflow, we can fabricate large numbers 
of microtissues and distributue them across experiemnts in time.  When needed, we can thaw 
microtissues and conduct high-throughput assessment of protein-, cell-, and tissue-level 
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Figure 8.2: Encapsulated cells remain highly viable and functional after cryopreservation in 
microtissues 
(A) Brightfield and widefield fluorescence imaging of microtissues with encapsulated NIH 3T3, 
MDA-MB-231, and NHLF cells (nuclei shown in blue). Calcein AM (green) shows that all cell 
types had high viability (greater than 83%) after 1 week of freezing and were over 90% viable 
after 1 week of cultur in standard conditions, which was comparable to tissues that never 
underwent freezing. (B) Compaction of encapsulated cells indicated that before and after 
cryopreservation, cells were similarly contractile, compacting microtissues at similar rates and 
with the same trajectories. Shown with standard error and an average of 82 microtissues per 
condition. (C) Brightfield and widefield fluorescence imaging of cell proliferation after 
cryopreservation. Proliferative capacity, as determined with a Click-It EdU assay (nuclei shown 
in blue, proliferating cells in magenta). All microtissues in all conditions had cells that 
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proliferated, indicating that cells retained their proliferative capacity after cryopreservation in the 
microtissues. All scale bars 100 µm. 
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Figure 8.3: Cryopreservation with repetitive thawing of liver carcinoma, HepG2  
To assess cell morphology of HepG2 in our constructs, we used immunofluorescence staining (a) 
for albumin (green) (scale bar = 100 µm). Although cells were distributed homogenously within 
the microtissues immediately after fabrication, culture of this cell line for two weeks resulted in 
heterogeneity for all conditions (low denoting low cell number phenotype, and high denoting high 
cell number phenotype).  We observed that CryostorCS10 does not perform as well for the 
HepG2 monoculture, but with the supporting 3T3-J2 cells this cryoprotectant results in tissues 
that are similar to the never-frozen controls.  The FBS/DMSO cryopreservation solution results in 
similar cell morphology and growth regardless of the 3T3-J2 cell layer.  We also assessed the 
impact these cryopreservatives have on CYP2A6 activity (b,c).  We found that for both 
cryoprotectants tested resulted in CYP2A6 activity that was equal to or greater than the never-
frozen control.  Both trends noted previously from the immunofluorescence staining were echoed 
in the CYP2A6 assessment, with Cryostor CS10 performing best in the co-culture condition, and 
the FBS/DMSO solution performing equally for both monoculture and co-culture.   
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Chapter 9: Overall conclusions 
High throughout systems for predictive drug screening and biological discovery 
are in critical need, as the current gold standard of 2D culture lacks physiological 
relevance in geometry and substrate interactions, leading to inaccurate drug screening 
results and slowing drug discovery. We present an alternative method that is accessible 
and affords physiologically relevant substrates for cell-ECM interactions. We showed 
that our method is biocompatible, with several cell types demonstrating high viability 
during and after the fabrication process.  
Additionally, because our microtissues are composed entirely of natural ECM, 
cells can interact with and remodel their environment. We used this to our advantage and 
to create the first of its kind, small-scale contraction assay. We demonstrated that our 
assay is more sensitive than the current gold standard for contraction assays. We also 
showed that our system can be used with studies for contraction inhibitors, demonstrating 
potential for high-throughput drug screening.  
Extracellular matrix remodeling can happen over short and long timescales. The 
first iteration of our platform supported short-term studies (<7 days), so we modified our 
platform to support long-term experiments using a low-adhesion microwell system to 
culture our collagen microtissues (detailed in Chapter 5). We used this improvement to 
the technology to further expand our breadth of readouts and methods for handling and 
storing microtissues.  
We then focused on building model systems for specific applications. We first 
used our system to create the first demonstration of natural ECM carriers for 
measurements of endothelial permeability. We showed that endothelial cells adhere to the 
collagen constructs, and remodel via ECM contraction and deposition of basement 
membrane proteins - two key functions that are difficult to recapitulate in vitro. We also 
used our platform to quantify macro molecular permeability and found our measurements 
to be similar to in vivo results. We also showed that our platform could be used to assess 
changes in endothelial permeability, validated with known modulators of endothelial 
permeability. This study demonstrates the potential of this platform to enable high-
throughput screening of functional readouts typically restricted to low-throughput 
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methods, and could be expanded further in the future to include precious cell sources like 
brain endothelial cells for mimics of the blood-brain barrier.  We continued to explore 
specific applications next with a liver model.  
Predictive systems for in vitro models of human liver toxicity are currently 
missing from the field of high-throughput screening and in vitro biology. We 
hypothesized that our system could be used to advance the goal of a predictive human 
hepatocyte model for toxicology studies. Working with the Khetani Lab at University of 
Illinois at Chicago (UIC), we translated our technology to their group conducted 
experiments collaboratively. We showed that the microtissues platform is compatible 
with PHHs and iHeps, and that in co-culture with 3T3-J2s these cells are viable and 
functional in our platform for long-term culture (21 days and 32 days respectively). We 
investigated the effect of combination of ECM components for PHHs and iHeps, 
demonstrating the potential for this platform to do combinatorial screens of ECM proteins 
in 3D microenvironments.  
We also examined the possibility of cryopreserving complete microtissue 
constructs, and found that cells remain viable and functionally proficient after thawing. 
We are continuing to expand this work for cells sources that are non-platable and/or 
difficult to expand, making the most efficient use of delicate and precious resources.   
This methodology also affords exciting opportunities to disseminate our technology 
further, as after construct fabrication, all methods are completed using standard cell 
culture plates and equipment and could be seamlessly translated into the workflow of any 
lab already setup for cell culture.  
The specific applications of this platform are broad, and we are continuing to 
develop new methods of patterning within the microtissues as well as the organ systems 
and biological phenomenon we are trying to mimic in vitro. We have collected 
preliminary data for explicitly patterning cells within microtissues, using two 
encapsulation steps to confine cells to a small portion of larger acellular constructs.  
Using this sequential encapsulation method, we will assess differences in cell distribution 
within our constructs over time, with cells responding to various growth conditions – the 
basis for our future 3D high-throughput 3D migration assay. We are eager to continue to 
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refine and expand the capabilities of our technology, as well as the in vitro biological 
systems we can generate with this platform. 
We have shown that for several applications, our microtissue platform can be 
used for similar readouts as larger-scale in vitro assays. In addition, because of the small 
size scale, we can create at least 2,000 times more replicates with the same initial volume 
of reagents. This is particularly important as we progress to working with precious cells 
and ECM sources. In the future, this could mean that patient samples could be evaluated 
using the outlined microtissue platform.  For example, to test the efficacy of a cancer 
treatment strategy, patient tumor cells could be encapsulated and cultured in microtissues 
under various treatment regimens, testing several treatment strategies simultaneously in 
vitro. Additionally, with advancements in induced pluripotent stem cell technology, cells 
from adults could be collected and differentiated toward different organs (e.g. brain, 
heart, liver, lungs), microtissues could be used to house these different cell types and 
examine patient-specific biology, as well as run studies for off-target effects (e.g. liver 
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